US20030013748A1 - Pharmaceutical compositions comprising tyrphostins - Google Patents
Pharmaceutical compositions comprising tyrphostins Download PDFInfo
- Publication number
- US20030013748A1 US20030013748A1 US10/141,086 US14108602A US2003013748A1 US 20030013748 A1 US20030013748 A1 US 20030013748A1 US 14108602 A US14108602 A US 14108602A US 2003013748 A1 US2003013748 A1 US 2003013748A1
- Authority
- US
- United States
- Prior art keywords
- mice
- formula
- cells
- doxorubicin
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 20
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title description 91
- 150000001875 compounds Chemical class 0.000 claims abstract description 38
- 210000000056 organ Anatomy 0.000 claims abstract description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 12
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 claims abstract description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 212
- 229960004679 doxorubicin Drugs 0.000 claims description 106
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 94
- 229960004316 cisplatin Drugs 0.000 claims description 94
- 238000011282 treatment Methods 0.000 claims description 40
- 230000006378 damage Effects 0.000 claims description 29
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 15
- 230000006907 apoptotic process Effects 0.000 claims description 15
- 229960004397 cyclophosphamide Drugs 0.000 claims description 15
- 229940127089 cytotoxic agent Drugs 0.000 claims description 15
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 13
- 239000002254 cytotoxic agent Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 229960004857 mitomycin Drugs 0.000 claims description 11
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 230000009931 harmful effect Effects 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000028709 inflammatory response Effects 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 230000005911 anti-cytotoxic effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 abstract description 17
- 230000002588 toxic effect Effects 0.000 abstract description 17
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 278
- 210000004027 cell Anatomy 0.000 description 124
- 238000002347 injection Methods 0.000 description 103
- 239000007924 injection Substances 0.000 description 103
- 229940090044 injection Drugs 0.000 description 95
- 238000007912 intraperitoneal administration Methods 0.000 description 72
- 206010028980 Neoplasm Diseases 0.000 description 39
- 230000000694 effects Effects 0.000 description 39
- 210000001185 bone marrow Anatomy 0.000 description 37
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 30
- 239000003981 vehicle Substances 0.000 description 29
- 230000002829 reductive effect Effects 0.000 description 23
- 210000002966 serum Anatomy 0.000 description 22
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 21
- 102100040247 Tumor necrosis factor Human genes 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 17
- 230000009467 reduction Effects 0.000 description 17
- 229940109239 creatinine Drugs 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 0 */C(C#N)=C(\[H])C[Ar] Chemical compound */C(C#N)=C(\[H])C[Ar] 0.000 description 14
- 108010082126 Alanine transaminase Proteins 0.000 description 14
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 231100000304 hepatotoxicity Toxicity 0.000 description 13
- 210000003734 kidney Anatomy 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 201000008808 Fibrosarcoma Diseases 0.000 description 12
- 206010019851 Hepatotoxicity Diseases 0.000 description 12
- 230000007686 hepatotoxicity Effects 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 11
- 210000000689 upper leg Anatomy 0.000 description 11
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 10
- 206010029155 Nephropathy toxic Diseases 0.000 description 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000007694 nephrotoxicity Effects 0.000 description 10
- 231100000417 nephrotoxicity Toxicity 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 10
- 210000001541 thymus gland Anatomy 0.000 description 10
- 108010062580 Concanavalin A Proteins 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 8
- 108090000340 Transaminases Proteins 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 210000002798 bone marrow cell Anatomy 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 8
- 102000003929 Transaminases Human genes 0.000 description 7
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 230000002556 myelotoxic effect Effects 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- 210000000813 small intestine Anatomy 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 208000001382 Experimental Melanoma Diseases 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 206010033128 Ovarian cancer Diseases 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010040070 Septic Shock Diseases 0.000 description 5
- 229940000635 beta-alanine Drugs 0.000 description 5
- 229940105442 cisplatin injection Drugs 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000003328 fibroblastic effect Effects 0.000 description 5
- 230000036303 septic shock Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 101100138645 Bacillus licheniformis pelA gene Proteins 0.000 description 4
- ZHWPTBJQTJMPJA-UHFFFAOYSA-N CC(=O)NCCCCC1=CC=CC=C1 Chemical compound CC(=O)NCCCCC1=CC=CC=C1 ZHWPTBJQTJMPJA-UHFFFAOYSA-N 0.000 description 4
- RARBUZWPZHQBHW-UHFFFAOYSA-N CC(N)=C(C#N)C#N Chemical compound CC(N)=C(C#N)C#N RARBUZWPZHQBHW-UHFFFAOYSA-N 0.000 description 4
- CRRHJAMDQMQGKG-UHFFFAOYSA-N CC1=C(C#N)C(N)=NN1 Chemical compound CC1=C(C#N)C(N)=NN1 CRRHJAMDQMQGKG-UHFFFAOYSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101100192384 Escherichia coli (strain K12) manY gene Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 206010027458 Metastases to lung Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 239000006184 cosolvent Substances 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 229940035756 doxorubicin injection Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 231100000234 hepatic damage Toxicity 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 230000008818 liver damage Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 101150044611 pel gene Proteins 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- BXRFQSNOROATLV-UHFFFAOYSA-N 4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1 BXRFQSNOROATLV-UHFFFAOYSA-N 0.000 description 3
- WQNALVVXNVBVSW-UHFFFAOYSA-N C.C.C.CC(N)=C(C#N)C#N.CC1=C(C#N)C(N)=NN1.CC1=NC2=C(C=CC=C2)S1.COOSC1=CC=CC=C1 Chemical compound C.C.C.CC(N)=C(C#N)C#N.CC1=C(C#N)C(N)=NN1.CC1=NC2=C(C=CC=C2)S1.COOSC1=CC=CC=C1 WQNALVVXNVBVSW-UHFFFAOYSA-N 0.000 description 3
- KQZCRXVJXGYIFM-UHFFFAOYSA-N CC(=O)NCC1=CN=CC=C1 Chemical compound CC(=O)NCC1=CN=CC=C1 KQZCRXVJXGYIFM-UHFFFAOYSA-N 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N CC(N)=O Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 230000037057 G1 phase arrest Effects 0.000 description 3
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 231100000518 lethal Toxicity 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001917 lymphotoxic effect Effects 0.000 description 3
- 231100000052 myelotoxic Toxicity 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- FZERHIULMFGESH-UHFFFAOYSA-N CC(=O)NC1=CC=CC=C1 Chemical compound CC(=O)NC1=CC=CC=C1 FZERHIULMFGESH-UHFFFAOYSA-N 0.000 description 2
- UZJLYRRDVFWSGA-UHFFFAOYSA-N CC(=O)NCC1=CC=CC=C1 Chemical compound CC(=O)NCC1=CC=CC=C1 UZJLYRRDVFWSGA-UHFFFAOYSA-N 0.000 description 2
- MODKMHXGCGKTLE-UHFFFAOYSA-N CC(=O)NCCC1=CC=CC=C1 Chemical compound CC(=O)NCCC1=CC=CC=C1 MODKMHXGCGKTLE-UHFFFAOYSA-N 0.000 description 2
- YXCRHNOACQLGPS-UHFFFAOYSA-N CC(=O)NCCCC1=CC=CC=C1 Chemical compound CC(=O)NCCCC1=CC=CC=C1 YXCRHNOACQLGPS-UHFFFAOYSA-N 0.000 description 2
- SKENXOKTZGFWLI-UHFFFAOYSA-N CC1=C(C#N)C([N+](=O)[O-])=NN1 Chemical compound CC1=C(C#N)C([N+](=O)[O-])=NN1 SKENXOKTZGFWLI-UHFFFAOYSA-N 0.000 description 2
- 206010048610 Cardiotoxicity Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XYUAXZDQSDTCHO-UHFFFAOYSA-N O=[SH](=O)C1=CC=CC=C1 Chemical compound O=[SH](=O)C1=CC=CC=C1 XYUAXZDQSDTCHO-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical compound C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 2
- 210000000107 myocyte Anatomy 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 208000018655 severe necrosis Diseases 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- ZFCFFNGBCVAUDE-UHFFFAOYSA-N 2-(benzenesulfonyl)acetonitrile Chemical compound N#CCS(=O)(=O)C1=CC=CC=C1 ZFCFFNGBCVAUDE-UHFFFAOYSA-N 0.000 description 1
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 1
- BWUIGISQVCIQBT-UHFFFAOYSA-N 3-fluoro-4-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=C(C=O)C=C1F BWUIGISQVCIQBT-UHFFFAOYSA-N 0.000 description 1
- AUBBVPIQUDFRQI-UHFFFAOYSA-N 3-hydroxy-4-nitrobenzaldehyde Chemical compound OC1=CC(C=O)=CC=C1[N+]([O-])=O AUBBVPIQUDFRQI-UHFFFAOYSA-N 0.000 description 1
- IPWGAPCYYMTTLT-UHFFFAOYSA-N 3-propylaniline Chemical compound CCCC1=CC=CC(N)=C1 IPWGAPCYYMTTLT-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N CC(N)=S Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 1
- DXYYSGDWQCSKKO-UHFFFAOYSA-N CC1=NC2=C(C=CC=C2)S1 Chemical compound CC1=NC2=C(C=CC=C2)S1 DXYYSGDWQCSKKO-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 206010011416 Croup infectious Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 231100000750 In vitro toxicology Toxicity 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000006000 Knoevenagel condensation reaction Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 201000010549 croup Diseases 0.000 description 1
- -1 cyano acetyl Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 108010052621 fas Receptor Proteins 0.000 description 1
- 102000018823 fas Receptor Human genes 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000009097 homeostatic mechanism Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000019189 interleukin-1 beta production Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- JQVMRGYDSQFFJC-UHFFFAOYSA-N n-benzyl-2-cyanoacetamide Chemical compound N#CCC(=O)NCC1=CC=CC=C1 JQVMRGYDSQFFJC-UHFFFAOYSA-N 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- BNHGNFYPZNDLAF-UHFFFAOYSA-N tricyanoaminopropene Chemical compound N#CCC(N)=C(C#N)C#N BNHGNFYPZNDLAF-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Definitions
- the present invention concerns compositions which are useful to counter damage caused by harmful agents, particularly anti-neoplastic agents used in cancer treatment, e.g. cytotoxic drugs. Damage in the context of the present invention means adverse effects on either cells, tissue or organs. The present invention also concerns therapeutic methods to counter such damage. Furthermore, the present invention concerns also novel compounds useful in such compositions and methods.
- harmful agents particularly anti-neoplastic agents used in cancer treatment, e.g. cytotoxic drugs.
- Damage in the context of the present invention means adverse effects on either cells, tissue or organs.
- the present invention also concerns therapeutic methods to counter such damage.
- the present invention concerns also novel compounds useful in such compositions and methods.
- Apoptosis or programmed cell death is a fundamental physiological mechanism of cell death regulated during embryonal development and normal homeostasis mechanisms within the body. Recent data indicated that the anti tumor effect of a variety of chemotherapeutic agents is related to their ability to induce apoptosis. The toxicity of these agents may also be related to the induction of apoptosis in normal cells.
- the present invention provides, by a first of its aspects, a pharmaceutical composition for countering, i.e. reducing or preventing, damage to cells or tissue comprising, as an active agent, an effective amount of a compound of the general formula I:
- Ar is a group of the formulae
- n is 0 or, when Ar has the formula (i) above, then n may also be 1, R is CN, —C(S)NH 2 , —C(O)NHR 3 or, when R 1 is 4-NO 2 and R 2 is H or 3-OH, then R may also be a group of the formula
- R 3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl
- R 1 and R 2 are each independently H, OH, NO 2 or, when R is CN, also CH 3 , F, or CF 3 , provided that both R 1 and R 2 are not simultaneously H. together with a pharmaceutically acceptable carrier.
- Said active agent and said pharmaceutical composition may be administered to or contacted with cells or tissue in a variety of conditions to reduce or prevent undesired damage to cells, tissues or organs.
- conditions are such which may lead to apoptosis.
- Preventing of undesired apoptosis is a specific embodiment of the invention.
- Such conditions may also be exposure of said cells, tissue or organ to harmful factors, which may be exogenous or endogenous factors, as well as other physiological conditions, which may lead to damage, e.g. change in temperature, impairment of blood flow, exposure an ionizing irradiation, etc.
- the damage to be prevented may also be a result of natural physiological deterioration processes, e.g. such occurring in cells, tissue or organs, maintained, grown or cultured ex vivo.
- the present invention also provides a method of treatment of an individual, for countering damage to cells, tissue or organ, comprising administering to the individual an effective amount of a compound having the general formula I.
- an effective amount should be understood as meaning an amount of the active compound, which is effective in countering damage manifested in either destruction of normal (non-diseased) cells or damage to a tissue or organ.
- the harmful factor may be an exogenous agent e.g., a therapeutic drug having a cytotoxic effect (e.g. anti-neoplastic drugs), irradiation, noxious chemicals, etc.
- the harmful factor may be endogenous, such as free radicals the level of which rises in the course of various metabolic or other disorders, auto-antibodies, cytokines, etc.
- compositions of the invention may be used in the framework of treatment of various diseases, disorders or conditions such as AIDS, conditions which may give rise to hepatotoxicity, radiation injuries, reducing or inhibiting damage to grafted cells or tissue as a result of graft rejection, for the treatment of intoxications, e.g,. paracetamol intoxication, for countering adverse effects of noxious solvents and carriers of therapeutic drugs, countering alcohol-caused damages, etc.
- the compositions may also be used for countering non-desired immune mediated reactions or an inflammatory response, e.g. septic shock, to reduce damage caused by autoimmune reactions and others.
- compositions of the invention also may be used in ex vivo preservation of cells, tissues or organs used for transplantation to reduce or prevent cell or tissue deterioration or death which may otherwise occur during the time they are kept ex vivo prior to transplantation, etc.
- compositions of the invention are especially useful to counter toxic effects of cytotoxic or anti-metabolic drugs, particularly such as used in cancer therapy. Occasionally, the pharmaceutical composition of the invention will be administered in conjunction with the cytotoxic drug.
- a pharmaceutical composition according to this embodiment may comprise such a drug in combination with a compound of above formula I.
- the compounds of formula I belong to a family of compounds known as Tyrphostin compounds (Levitzki, A. and Gazit, A. Science, 267:1782, 1995).
- a compound of Formula I will be referred to as “Tyrphostin” and compositions comprising such compounds will at times be referred to as “Tyrphostin compositions”.
- Preferred compounds of formula I for use in the compositions are those wherein R is CN, —C(S)NH 2 , —C(O)NHCH 2 C 6 H 5 or a group of the formula
- R 1 is 4-NO 2 and R 2 is H.
- tyrphostins are shown in compound Table I. Some of the tyrphostins shown in Compound Table I are novel, and these novel tyrphostins are shown also in Compound Table II. Compound Table I No. R R1 R2 m.p. ° C.
- tyrphostins in accordance with the invention are the compounds designated as AG1714, AG1744, AG1801 and AG1843 in the above “Compound Table I”. Out of these four compounds, the latter two are novel.
- the tyrphostins of formula I may be administered to the patient in combination with anothcr treatment, e.g,. in combination with a cytotoxic drug or irradiation.
- anothcr treatment e.g. in combination with a cytotoxic drug or irradiation.
- the tyrphostins may be administered simultaneously with or at a different time than the other treatment, so as to yield a maximum effect.
- a particular example is administration of the tyrphostins prior to the other treatment, e.g. several hours prior to the irradiation or to the administration of the cytotoxic drug.
- tyrphostins of formula I when administered together with another therapeutic agent, they do not reduce the therapeutic activity of the other agent, but rather act in reducing its undesired toxic side effects to normal cells or tissue. This means that the therapy with the therapeutic agent will still achieve the same desired therapeutic effect, at the same dosage.
- a chemotherapeutic drug the administration of a tyrphostin will not, or may only minimally affect the effect of the drug in reducing the tumor load or preventing tumor growth or tumor recurrence, at a given administration dosage. In some cases, however, administration of the tyrphostins even intensifies the therapeutic effect of the treatment.
- the overall effect of the tyrphostins, in such a combination therapy is thus the increase in the therapeutic index of another therapy, namely, increase in the ratio between the therapeutic effect of the therapy to its undesired toxic side effects.
- the increase in therapeutic index may at times be used to advantage of increasing the dosage of the therapeutic agent, e.g. the dosage of the cytotoxic agent or radiation, without a concurrent increase in undesired toxic side effects.
- the tyrphostins according to the invention may be administered either in a single dose or may be given repetitively over a period of time, e.g. prior, during and after the treatment with a cytotoxic agent or irradiation.
- a preferred mode of administration of the tyrphostins to humans is intravenously, although by a proper formulation, they may also be administered by other administration modes, e.g. intramuscularly, intraperitoneally or orally.
- tyrphostin compositions will typically contain a single tyrphostin compound it is possible at times to include in the composition and or co-administer two or more tyrphostins which act together in a synergistic or additive manner to counter damages caused, e.g. by a therapeutic treatment.
- FIG. 1A is a graphic representation showing the mortality of mice treated with doxorubicin as compared to the mortality of mice receiving a single injection of AG1714 two hours before treatment with doxorubicin.
- FIG. 1B is a graphic representation showing, the mortality of mice treated with cisplatin as compared to the mortality of mice receiving a single injection of AG1714 two hours before treatment with cisplatin.
- FIG. 2 is a graphic representation showing the mortality of mice receiving 10 i.p. injections of doxorubicin (5 mg/kg) for a period of 21 days (cumulative dose 50 mg/kg) as compared to the mortality of mice treated as above but receiving an i.p. injection of AG1714 (5 mg/kg) two hours prior to each doxorubicin injection.
- FIG. 3 is a graphic representation showing the mortality of mice treated with cisplatin alone or with cisplatin and AG1801 over a period of ten days after cisplatin administration.
- FIG. 4 is a graphic representation showing the mortality of mice treated with doxorubicin alone or with tyrphostins and doxorubicin over a period of ten days after doxorubicin administration.
- FIG. 5 is a graphic representation showing the effect of a number of tyrphostins on the toxic effect of cisplatin in kidneys of treated mice. The toxic effect is measured by the level of creatinine detected in the serum of the treated mice, a high level of creatinine indicating kidney damage (nephrotoxicity).
- FIG. 6 is a graphic representation showing the level of creatinine (FIG. 6A) and blood urea nitrogcn (BUN) (FIG. 6B) (which are indicative of nephrotoxicity) in serum of mice receiving either cisplatin alone, AG1714 alone or a combination of cisplatin and AG1714.
- the levels of creatinine and BUN were compared to the levels of the same substances in serums of control mice receiving the vehicle only.
- FIG. 7 is a photograph showing histopathological analysis of kidneys (FIG. 7A-C) and small intestines (FIG. 7D-F) of mice administered with cisplatin alone or with the tyrphostin AG1714 prior to the administration of cisplatin. Final magnification ⁇ 400;
- FIG. 7A kidneys of normal non-treated mice
- FIG. 7B kidneys of mice receiving cisplatin alone showing large proteinaceous plaques in the proximal tubules
- FIG. 7C kidneys of mice receiving AG1714 prior to cisplatin administration showing normal kidney structure
- FIG. 7D small intestines of non-treated mice
- FIG. 7E small intestine of mice receiving cisplatin alone showing severe necrosis and damage
- FIG. 7F a small intestine of mice treated with AG1714 prior to cisplatin administration showing normal small intestine structure
- FIG. 8 is a graphic representation showing the level of two transaminases, Aspartic transaminasc (AST) and Alanine-transaminase (ALT) in serum of mice receiving an injection of anti-FAS antibody alone or in combination with the tyrphostin AG1801. High levels of the transaminases indicate anti-FAS antibody induced damage to the liver (hepatotoxicity);
- FIG. 9 is a graphic representation showing the level of two transaminases AST and ALT in serum of mice receiving an injection of anti-FAS antibody alone or in combination with the tyrphostin AG1714; High levels of the transaminases indicate anti-FAS antibody induced damage to the liver (hepatotoxicity);
- FIG. 10 is a graphic representation showing the level of AST and ALT in serum of mice treated with Con A alone or in combination with AG1714;
- FIG. 11 is a graphic representation showing the level of AST and ALT in serum of mice treated with TNF/GalN or in combination with the tyrphostin AG1714;
- FIG. 12 is a graphic representation showing the number of bone marrow nucleated cells (FIG. 12A) or the number of colony forming units (CFU) (FIG. 12B) in femur bone marrow of mice treated with doxorubicin alone, AG1714 along or with their combination;
- FIG. 13 is a graphic representation showing the number of nucleated cells in bone marrow of mice treated with doxorubicin alone or with AG1714 and doxorubicin:
- FIG. 13A shows the number of nucleated cells in bone marrow of the mice receiving different doses of doxorobucin
- FIG. 13B shows the number of nucleated cells in bone marrow, of the treated mice at different periods of time after treatment with doxorubicin;
- FIG. 14 is a graphic representation showing the weight of the spleen (FIG. 14A) and thymus (FIG. 14B) of mice treated either with doxorubicin alone or with AG1714 prior to doxorubicin administration;
- FIG. 15 is a graphic representation showing the number of bone marrow nucleated cells in the femurs of mice treated with 5FU alone or with 5FU and AC1714;
- FIG. 16 is a graphic representation showing the number of bone marrow nucleated cells in the femurs of mice treated with mitomycin-C alone or with mitomycin-C and AG1714;
- FIG. 17 is a graphic representation showing the number of nucleated cells in bone marrow of mice treated with doxorubicin alone or with AG1801 at different doses prior to doxorubicin administration;
- FIG. 18 is a graphic representation showing the number of nucleated cells in bone marrow of irradiated mice (300R) and of mice treated with the tryphostin AG1714 before irradiation;
- FIG. 19 is a graphic representation showing the number of cells in bone marrow of irradiated mice (450R) and of mice treated with tyrphostin AG1714 before irradiation;
- FIG. 20 is a graphic representation showing the mortality of mice after lethal irradiation (800R) as compared to the mortality of mice treated with tyrphostin AG1714 prior to irradiation over a period of 23 days after irradiation;
- FIG. 21 is a graphic representation showing the weight of lungs of mice inoculated with MCA-105 fibrosarcoma cells (FIG. 21A), Lewis lung carcinoma cells (FIG. 21B) or B-16 melanoma cells (FIG. 21C) and treated with either cisplatin alone, AG1714 alone or with a combination of cisplatin and AG1714;
- FIG. 22 is a graphic representation showing the weight of nude mice bearing the SK-28 human melanoma tumors and treated with doxorubicin, AG1714 or their combination;
- FIG. 23 is a graphic representation showing the volume of the human ovary carcinoma tumor (OVCAR-3) in mice treated either with cisplatin alone, with AG1714 alone or with their combination;
- FIG. 24 is a graphic representation showing the volume of the OVCAR-3 tumor in mice receiving repetitive administration of the treatments described in FIG. 23 above;
- FIG. 25 is a graphic representation showing the weight of lungs in MCA-105 fibrosarcoma tumor bearing mice treated with cisplatin alone, AG1801 alone or a combination of both (FIG. 25A) or with doxorubicin alone, AG1801 alone or their combination (FIG. 25B);
- FIG. 26 is a graphic representation showing the weight of lungs of mice treated with cisplatin alone, AG1801 alone or a combination of both;
- FIG. 27 is a graphic representation showing the number of colony forming units (CFU) in cultures of bone marrow cells grown with or without various concentrations of AG1714;
- FIG. 28 is a graphic representation showing the viability of thymocytes grown with or without AG1714 at various periods of time after the addition of AG1714 to the cells;
- FIG. 29 is a graphic representation showing the number of beats per minute in cardiomyocyte cultures grown with or without AG1714 as an indication of the viability of the cells;
- FIG. 30 is a graphic representation showing the percent lysis measured by percent of specific 51 Cr release of target EL-4 cells by murine peritoneal exudate cytotoxic lymphocytes (PEL) in the presence or absence of AG1714.
- CD1 mice were divided into the following five groups:
- mice Groups of CD1 mice, each comprising three mice were injected i.p. with a dose of 14 mg/kg of cisplatin.
- the level of creatinine was determined in the serum of each mouse four days after administration of the cisplatin using a commercial kit by Sigma.
- the creatinine level of about 2 mg/dl detected in the serum of mice receiving cisplatin alone indicates that there is about a 50% reduction in the kidney function of these mice.
- the level of creatinine measured in the serum of many of the mice receiving an injection of an tyrphostin before the cisplatin injection was lower than the creatinine levels in the serum of mice receiving cisplatin alone.
- injection of the tyrphostins prior to the cisplatin injection reduces the toxic effect of cisplatin on kidney function.
- the reducing effect on the nephrotoxicity of cisplatin varied between the different tyrphostins. For example, AG1824, AG1744, AG1751, AG1714, AG1823 AG1782, AG1801, markedly reduced the nephrotoxicity of cisplatin bringing the creatinine levels in the serum to those of control mice.
- CD1 female mice were injected either with cisplatin alone or with a single injection comprising either the tyrphostin AG1843 or AG1714 two hours before injection of cisplatin and the level of the creatinine in their serum was tested as explained above.
- CD1 mice were injected (i.p.) with cisplatin (14 mg/kg) or first with AG1714 (10 mg/kg) and two hours after with cisplatin as explained above.
- Mice in the control group received injections of the vehicle only (a stock solution of ethanol: chemaphore (50:50) diluted with saline).
- a stock solution of ethanol: chemaphore (50:50) diluted with saline Four days after administration of the cisplatin, several parameters indicating nephrotoxicity and liver injury were measured in the serums of each of the mice 4 days after cisplatin administration.
- the parameters showing nephrotoxicity of cisplatin were creatinine and blood urea nitrogen (BUN) and the parameters indicating damage to the liver were the hepatic transaminases alanine-transaminase (ALT) and aspartic transaminase (AST) measured by standard methods. Each group consisted of three mice and the results are shown as mean levels of the measured parameter ⁇ SD.
- CD1 mice were injected with 14 mg/kg of cisplatin or first with a single i.p. injection of the tyrphostin AG1714 and two hours later an injection of 14 mg/kg of cisplatin. Histopathological analysis of the kidneys and small intestines of the non-treated and treated mice was performed using slices from formaline fixed tissues stained with hematoxylin eosin.
- kidneys of mice receiving cisplatin alone showed large proteinaceous plaques in the proximal tubals (7B) as well as the appearance of granular material in the columnar epithel.
- kidneys of the mice receiving AG1714 injection prior to the cisplatin administration (7C) showed no damage and their structure was similar to that of control mice (7A).
- mice receiving cisplatin alone (7E) showed severe necrosis and disintegration of the columnar intestinal epithelial cells as compared to the small intestines of mice receiving AG1714 prior to the cisplatin administration (7F) which showed a normal structure similar to that seen in the small intestine of non-treated mice (7D).
- the FAS antigen is a cell surface protein belonging to the two factor/nerve (growth factor receptor family and have been shown to mediate apoptosis (Itoh, N. et al., Cell, 66:233-243(1991)). Intraperitoneal administration of an anti-FAS antibody into mice was shown to cause severe damage of the liver by apoptosis.
- mice were injected i.p. either with AG1801 (5 mg/kg) or with AG1714 (5 mg/kg) and two hours later with an i.p. injection of an anti-FAS antibody at a dose of 5 ⁇ g/mouse. Another group of mice received only an injection of anti-FAS antibody with no prior treatment with the tyrphostins.
- mice Five hours after injection of the anti-FAS antibody, the animals were sacrificed and the level of two transaminases AST and ALT in the serum of the sacrificed mice was determined: a high level of these transaminases indicating hepatotoxicity (Ogasaware, J., et al., Nature, 364:806-809, 1993).
- T-cell mediated hepatotoxicity is a complication of various disorders and diseases such as Hepatitis B virus infection. Such hepatotoxicity can be induced by injection of Conavalin A (Con A). The effect of AG1714 on Con A induced hepatotoxicity on mice was determined in the following way (see Tiegs, G. et al., J. Clin. Invest., 90:196-203, 1992).
- CD1 mice were divided into the following groups:
- liver damage may be induced by various immune mechanisms such as cytokines as well as by a variety of other agents known to exert an apoptotic effect (e.g. alcohol or paracetemol).
- cytokines e.g. IL-12
- other agents known to exert an apoptotic effect e.g. alcohol or paracetemol.
- a model for such liver injury induced by apoptosis was developed in which the hepatic damage is induced in vivo by the injection of galactosamine and TNF- ⁇ (see Leist, M., et al., J. Immunol., 153:1778-1783, 1994).
- mice were divided into the following four groups:
- mice receiving an i.v. injection of human TNF- ⁇ (0.25 ⁇ g/mouse) in combination with galactosamine (GaIN) (18 ml/mouse, i.p.); and
- mice receiving the treatment of group iii above together with an injection of AG1714 (10 mg/kg) injected i.p. two hours prior to TNF/GaIN injection. 7 hours after injection of the TNF/GaIN, the serum levels of the liver enzymes AST and ALT in the serum of the various treated mice was determined as described above.
- CD1 mice were divided into the following groups:
- CD1 mice received either a single i.p. injection of doxorubicin (10 mg/kg) or first single i.p. injection of AG1714 (20 mg/kg) and two hours later, an i.p. injection of doxorubicin (10 mg/kg). 72 hours after doxorubicin administration the mice were sacrificed and the weight of the spleen and thymus of the mice was determined as parameters of lymphotoxicity. Each experimental group consisted of three mice and the results arc mean no. of cells ⁇ SD. As control, the mice received an injection of the vehicle only instead of doxorubicin.
- CD1 mice were injected with a single i.p. injection of cyclophosphamide at a dose of 50 mg/kg and divided into the following groups;
- mice 72 hours after cyclophosphamide administration the mice were sacrificed and the nucleated cells in the bone marrow, spleen and thymus of the mice were counted. Each experimental group consisted of three mice and the results shown are the mean number of cells in a group ⁇ SD.
- CD1 female mice were divided into the following groups:
- mice Five days after the administration of 5 FU to the mice, the mice were sacrificed and the number of nucleated cells in the bone marrow of one femur, were counted. Each group of mice consisted of two or three mice and the results shown are the mean number of cells counted ⁇ SD.
- CD1 female mice were divided into the following groups:
- mice were sacrificed and the number of nucleated cells in the bone marrow of one femur, were counted.
- Each group of mice consisted of two or three mice and the results shown are the mean number of cells counted ⁇ SD.
- mice receiving mitomycin-C alone showed a very low count of nucleated cells in their bone marrow. While administration of AG1714 alone had no effect on the mice, its administration prior to the administration of mitomycin-C to the mice resulted in a reduction in the myelotoxic effect of the mitomycin-C in these mice and provided almost full protection from the harmful effects of the mitomycin-C bringing the nucleated cell count in the bone marrow of these mice to the level of control mice receiving the cosolvent only.
- CD1 mice irradiated with a radiation dose of 300R using a cobalt source were divided into two groups:
- a third group of mice received only a single injection of AG1714 (20 mg/kg) and a fourth group of mice served as control mice which were not treated.
- mice were sacrificed and the number of cells in the bone marrow of one femur were counted.
- irradiation of the mice with 300R caused a decrease in the number of cells in the bone marrow of these mice as compared to untreated mice or mice treated only with AG1714.
- Reconstitution of cells in the bone marrow of the irradiated mice began about five days after their radiation.
- Treatment of the irradiated mice with AG1714 prevented the decrease in the number of cells in the bone marrow of the irradiated mice and caused a very significant enhancement of the number of cells in their bone marrow.
- the tyrphostin AG1714 has a protective effect against myelotoxicity caused by irradiation.
- the number of cells in the bone marrow of mice irradiated with 450R was significantly reduced five days after radiation indicating a severe myelotoxic effect of the irradiation on these mice.
- Five days after irradiation reconstitution of the number of cells in the bone marrow began but 18 days after radiation, the number of cells in the bone marrow of the irradiated mice still remained significantly lower than the number of cells in the bone marrow of non-treated mice or mice receiving AG1714 alone.
- myelotoxic effect was also seen until five days after radiation.
- CD1 mice were irradiated with a lethal 800R dose using a cobalt source, and divided into two groups:
- mice Each croup of mice consisted of 10 mice and the % mortality in each group was tested by scoring the number of dead mice each day after irradiation.
- Cisplatin (4 mg/kg) was injected i.p. 4 days after tumor inoculation. AG1714 (20 mg/kg) or vehicle was injected i.p. 2 hours prior to cisplatin. Twenty-four days after tumor inoculation, mice were sacrificed, lungs weighed and the number of metastases were scored. Each group contained 5 mice and the results are expressed as the means lungs' weights ⁇ SE.
- Cisplatin (4 mg/kg) or AG1714 (20) mg/kg) alone were not effective against established lung metastases of B-16 melanoma (FIG. 21C). Combined treatment with these agents was more effective than treatment with each agent alone.
- CD1 athymic mice (nu/nu) were inoculated i.v. with 4 ⁇ 10 5 /mouse SK-28 human melanoma.
- Doxorubicin (4 mg/kg) was injected i.p. 4 days after tumor inoculation.
- AG1714 (20 mg/kg) or vehicle were injected 2 hours prior to doxorubicin.
- the weights of the treated mice lungs and number of metastases in the lungs were determined 24 days after tumor inoculation. Each group contained 5 mice and the results are expressed as means ⁇ SE.
- doxorubicin markedly suppressed the growth of the SK-28 tumor whereas AG1714 by itself had a small anti-tumor effect. Pretreatment with AG1714 did not impair the effect of doxorubicin alone in the suppression of the growth of this tumor.
- Athymic mice were inoculated subcutaneously (s.c.) with human ovary carcinoma (OVCAR-3) cells (3 ⁇ 10 6 cells/site).
- Cisplatin (4 mg/kg) was injected 4 days after tumor inoculation.
- AG1714 (20 mg/kg) or vehicle was injected i.p. 2 hours prior to cisplatin.
- mice were injected i.v. with 2 ⁇ 10 5 B-16 melanoma cells and 4 days after tumor inoculation each mouse received a single i.p. injection of doxorubicin (4 mg/kg, or 8 mg/kg). Two hours prior to the doxorubicin injection, each mouse was injected i.p. with AG1714 at a dose of 20 mg/kg.
- Murine bone marrow nucleated cells were prepared by gradient centrifugation on histopaque. The cells were then divided into two groups:
- ii Cells incubated for one hour in growth medium with the addition of various concentrations (5 ⁇ M; 10 ⁇ M or 20 ⁇ M) of the tyrphostin AG1714.
- CFU colony forming units
- the plating, efficiency (determined by the number of CFU per 10 5 nucleated cells) of the cultures to which AG1714 was added was significantly enhanced as compared to that of the cells grown in growth medium alone.
- the tyrphostin AG1714 enables longer preservation of bone marrow cell culture.
- Thymocytes were prepared from thymuses of young CD1 mice at a concentration of 3 ⁇ 10 6 cell/ml in RPNI1640 growth medium containing 5% FCS. The cells were divided into two groups:
- the number of beats per minute of the myocyte clusters in each culture was determined 16 hours and 40 hours after the addition of the tyrphostins to the cells.
- tyrphostins AG1714 and AG1801 In order to study the toxic effects of the tyrphostins AG1714 and AG1801, the tyrphostins were injected to ICR mice 3 times a week over a period of five weeks. Each injection contains 20 mls. of the tyrphostins which was prepared in the vehicle propylene carbonate:cremophore (40/60) diluted 1:20 with saline/bicarbonate.
- mice In order to test the toxic effect of the cumulative administration of the tyrphostins, various parameters of the injected mice were determined including their weight, weight of their internal organs (thymus, spleen, kidney), full blood chemistry, number of bone marrow cells, etc.
- Murine peritoneal exudate cytotoxic lymphocytes (PEL) capable of specific lysis of EL-4 cells were prepared and tested as described in Lavy, R. et al., J. Immunol. 154:5039-5048, 1995.
- the EL-4 cells were divided into cells which were incubated with PELs alone, cells which were incubated with AG1714 (20 ⁇ M) and then with PELs and cells which were incubated with AG1714 (50 ⁇ M) and then with PELs.
- the lysis of the target EL-4 cells was determined using the specific 51 Cr release assay.
- tyrphostins may be useful for reducing immune mediated rejection of transplants, in cases of autoimmunity and in conditions involving specific immune activity against cells (e.g. anti-CD4 cells such as in the case of AIDS).
- A9 mouse fibroblastic cells were incubated for two hours with cycloheximide (50 ⁇ g/ml) after which the various tyrphostins were added at a final concentration of 20 ⁇ M except AG1801 that was added at the final concentration of 5 ⁇ M.
- TNF- ⁇ was added to the cells at a concentration of 0.2 ng/ml and the cells were incubated for an additional ten hours.
- the cell cultures were analyzed by FACS using propidium iodide and the extent of apoptosis in each of the cell cultures (seen as DNA fragmentation) was determined (see Novogrodsky, A., et al, Science, 264:1319-1322, 1994).
- mice injected with LPS which induces TNF toxicity in vivo.
- E.coli LPS the concentration of 1.3 mg/mouse was injected i.p. to CD1 mice. While control mice were injected in addition with the vehicle only, the remaining mice were injected with the various tyrphostins (20 mg/kg) i.p. two hours prior to LPS injection.
- IL-1 is one of the main mediators of septic shock in vivo.
- PBM peripheral blood monocytes
- tyrphostins may be useful in reducing or preventing the development of septic shock during an inflammatory response.
- the tyrphostins may also be useful as anti-inflammatory agents and in counteracting pathogenic effects mediated by various cytokines (c.g. TNF and IL-1) which occur for example in autoimmunity.
Abstract
Compounds useful for countering undesired toxic effects to cells, tissues or organs having formula (I) wherein: Ar is a group of formulae (i) or (ii), n is O or, when Ar has formula (i) above, then n may also be 1, R is CN, —GC(S)NH2, —C(O)NHR3 or, when R1 is 4—NO2 and R2 is H or 3—OH, then R may also be a group of formulae (iii), (iv), (v), (vi) where R3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl; R1 and R2 are each independently H, OH, NO2 or, when R is CN, also CH3, F, or CF3, provided that both R1 and R2 are simultaneously H.
Description
- The present invention concerns compositions which are useful to counter damage caused by harmful agents, particularly anti-neoplastic agents used in cancer treatment, e.g. cytotoxic drugs. Damage in the context of the present invention means adverse effects on either cells, tissue or organs. The present invention also concerns therapeutic methods to counter such damage. Furthermore, the present invention concerns also novel compounds useful in such compositions and methods.
- Most of the commonly used antineoplastic treatments, including chemotherapy and radiation, have adverse toxic effects, manifested on dividing cells and in the function of certain organs. Cells which are particularly affected by such treatment are bone marrow cells, skin cells and cells of the gastrointestinal tract epithelium. In addition, such treatments often cause damage to specific organs, such as the kidney and liver. As a result of such toxic effects, the therapeutic index of such treatments is limited.
- It is a long felt want in medical research to try and develop treatment modalities and means which will reduce the unwanted toxic side effects, without affecting the therapeutic activity of the drugs, thus increasing their therapeutic index.
- Apoptosis or programmed cell death is a fundamental physiological mechanism of cell death regulated during embryonal development and normal homeostasis mechanisms within the body. Recent data indicated that the anti tumor effect of a variety of chemotherapeutic agents is related to their ability to induce apoptosis. The toxicity of these agents may also be related to the induction of apoptosis in normal cells.
- Preliminary reports have described use of various pharmacological agents for the prevention of nephrotoxicity resulting from the use of anti-cancer drugs (Skinner, R.,Current Opinion in Oncology, 7:310-315, 1995). Attempts were made to counteract the severe chronic proximal tubular toxicity resulting from use of the cytotoxic drug Cisplatin. In in vivo experiments in rats, para-aminobenzoic acid (PABA) co-administered together with cisplatin resulted in reduced nephrotoxicity of the cisplatin without reducing its anti-tumor activity. Other agents such as mitimazole, chloropromazin and L-arginine were also administered to animals in various in vivo experiments carried out in connection with toxicity of cisplatin resulting in only preliminary non-conclusive findings.
- The drug amifostine which is dephosphorylated to yield a thiol moiety was also used for reducing anti-toxic effects of anti-neoplastic drugs (Cancer Res., 55:4069, 1995).
-
- wherein:
-
-
- where R3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
- R1 and R2 are each independently H, OH, NO2 or, when R is CN, also CH3, F, or CF3, provided that both R1 and R2 are not simultaneously H. together with a pharmaceutically acceptable carrier.
- Said active agent and said pharmaceutical composition may be administered to or contacted with cells or tissue in a variety of conditions to reduce or prevent undesired damage to cells, tissues or organs. Examples of such conditions are such which may lead to apoptosis. Preventing of undesired apoptosis is a specific embodiment of the invention. Such conditions may also be exposure of said cells, tissue or organ to harmful factors, which may be exogenous or endogenous factors, as well as other physiological conditions, which may lead to damage, e.g. change in temperature, impairment of blood flow, exposure an ionizing irradiation, etc. The damage to be prevented may also be a result of natural physiological deterioration processes, e.g. such occurring in cells, tissue or organs, maintained, grown or cultured ex vivo.
- The present invention also provides a method of treatment of an individual, for countering damage to cells, tissue or organ, comprising administering to the individual an effective amount of a compound having the general formula I.
- The term “effective amount” should be understood as meaning an amount of the active compound, which is effective in countering damage manifested in either destruction of normal (non-diseased) cells or damage to a tissue or organ.
- The harmful factor may be an exogenous agent e.g., a therapeutic drug having a cytotoxic effect (e.g. anti-neoplastic drugs), irradiation, noxious chemicals, etc. In addition, the harmful factor may be endogenous, such as free radicals the level of which rises in the course of various metabolic or other disorders, auto-antibodies, cytokines, etc.
- The pharmaceutical compositions of the invention may be used in the framework of treatment of various diseases, disorders or conditions such as AIDS, conditions which may give rise to hepatotoxicity, radiation injuries, reducing or inhibiting damage to grafted cells or tissue as a result of graft rejection, for the treatment of intoxications, e.g,. paracetamol intoxication, for countering adverse effects of noxious solvents and carriers of therapeutic drugs, countering alcohol-caused damages, etc. Furthermore, the compositions may also be used for countering non-desired immune mediated reactions or an inflammatory response, e.g. septic shock, to reduce damage caused by autoimmune reactions and others. Finally, the pharmaceutical compositions of the invention also may be used in ex vivo preservation of cells, tissues or organs used for transplantation to reduce or prevent cell or tissue deterioration or death which may otherwise occur during the time they are kept ex vivo prior to transplantation, etc.
- The pharmaceutical compositions of the invention are especially useful to counter toxic effects of cytotoxic or anti-metabolic drugs, particularly such as used in cancer therapy. Occasionally, the pharmaceutical composition of the invention will be administered in conjunction with the cytotoxic drug. A pharmaceutical composition according to this embodiment may comprise such a drug in combination with a compound of above formula I.
- The compounds of formula I belong to a family of compounds known as Tyrphostin compounds (Levitzki, A. and Gazit, A.Science, 267:1782, 1995). In the following text, a compound of Formula I will be referred to as “Tyrphostin” and compositions comprising such compounds will at times be referred to as “Tyrphostin compositions”.
- Out of the tyrphostins of formula I, some are known, albeit for uses other than those provided by the invention, and others are novel. The novel tyrphostins, which constitute another, independent aspect of the invention, are those of formula I, wherein Ar, R1 R2 and R3 are as defined above, with the provisos that
-
- b) when R is CN and n is 0, then
- (ba) if one of R1 and R2 is H or OH, then the other cannot represent NO2;
- (bb) if one of R1 and R2 is H or F, then the other cannot represent H or F; and
- c) when R1 is 4-NO2, R2 is H and n is 0, then R cannot represent —C(O)NH2 or —C(S)NH2.
-
- and n is 0, R1 is 4-NO2 and R2 is H.
- Examples of tyrphostins are shown in compound Table I. Some of the tyrphostins shown in Compound Table I are novel, and these novel tyrphostins are shown also in Compound Table II.
Compound Table I No. R R1 R2 m.p. ° C. Ref1 AG1714 CN 4-NO2 H 153 1 AG1791 4-NO2 H 238 2 AG1744 4-NO2 H 277 3 AG1820 4-NO2 H 103 4 AG1822 4-NO2 H 220 — AG1801 4-NO2 H 181 — AG1824 4-NO2 H 238 — AG1823 4-NO2 H 187 — AG1798 4-NO2 H 98 — AG1745 4-NO2 H 148 — AG1843 4-NO2 H — — AG126 CN 4-NO2 3-OH 176 5 AG1719 4-NO2 3-OH 215 — AG1720 4-NO2 3- OH 105 — AG1759 CN 4-NO2 3-CH3 97 — AG1762 CN 4-NO2 3- F 120 — AG1606 4-NO2 3-OH 148 — AG1821 4-NO2 3-OH 178 6 AG1781 CN 3-NO2 H 90 10 AG127 CN 3-NO2 4-OH 175 11 AG178 CN 4-F H 114 11, 12 AG1754 CN 3-F 4-F 57 13 AG1755 CN H 4-CF3 95 — AG1799 CN 4-NO2 158 — -
Compound Table II (Novel Compounds) No. R R1 R2 m.p. ° C. AG1822 4-NO2 H 220 AG1801 4-NO2 H 161 AG1824 4-NO2 H 238 AG1823 4-NO2 H 187 AG1798 4-NO2 H 98 AG1745 4-NO2 H 148 AG1843 4-NO2 H — AG1719 4-NO2 3-OH 215 AG1720 4-NO2 3- OH 105 AG1759 CN 4-NO2 3-CH3 97 AG1762 CN 4-NO2 3- F 120 AG1606 4-NO2 3-OH 148 AG1755 CN H 4-CF3 95 AG1799 CN 4-NO2 158 - 1. Mowry, D. T.,J. Am. Chem. Soc., 67:1050, 1945
- 2. Zabichy, J.,J. Chem. Soc., 683, 1961.
- 3. Bronskill, J. S., Dc A., and Ewing, D. F.,J. Chem. Soc. Perkin, Trans. I., 629, 1978
- 4. Junck, H., and Wolny, B.,Monat. Chem., 107:999, 1976
- 5. Novogrodsky, A.. Vanichkin, A., Patya, M., Gazit, A., Osherov, N. and Levitzki, A.,Science, 264:1319, 1994
- 6. Sakamoto, M., et al.,J. Chem. Soc., Perkin Trans I., 1759, 1995
- 7. (a) Flenner, A. L., C. A. 63:13,278, 1965
- (b) Lythgoe, K. Todd, A. and Tapham, C.J. Chem. Soc., 515, 1944
- 8. Drabek, J. and Meyer, A., C. A., 89:152,719, 1978
- 9. Gazit, A., et al.,J. Med. Chem., 34:1896, 1991
- 10. Carson, B. B., and Staughton, R. W.,J. Am. Chem. Soc., 50:2825, 1928.
- 11. Gazit, A., et al.,J. Med. Chem., 32:2344, 1989
- 12. Weinberger, M. A., and Higgin, R. M.,Can. J. Chem., 43:2585, 1965
- 13. Blox Ram, J., Dell, C. P., and Smith, C. W.,Heterocycles, 38:400, 1994.
- Particularly preferred tyrphostins in accordance with the invention are the compounds designated as AG1714, AG1744, AG1801 and AG1843 in the above “Compound Table I”. Out of these four compounds, the latter two are novel.
- The tyrphostins of formula I may be administered to the patient in combination with anothcr treatment, e.g,. in combination with a cytotoxic drug or irradiation. In such a combination treatment the tyrphostins may be administered simultaneously with or at a different time than the other treatment, so as to yield a maximum effect. A particular example is administration of the tyrphostins prior to the other treatment, e.g. several hours prior to the irradiation or to the administration of the cytotoxic drug.
- It was found in accordance with the invention that when the tyrphostins of formula I are administered together with another therapeutic agent, they do not reduce the therapeutic activity of the other agent, but rather act in reducing its undesired toxic side effects to normal cells or tissue. This means that the therapy with the therapeutic agent will still achieve the same desired therapeutic effect, at the same dosage. For example, in the case of a chemotherapeutic drug, the administration of a tyrphostin will not, or may only minimally affect the effect of the drug in reducing the tumor load or preventing tumor growth or tumor recurrence, at a given administration dosage. In some cases, however, administration of the tyrphostins even intensifies the therapeutic effect of the treatment. The overall effect of the tyrphostins, in such a combination therapy, is thus the increase in the therapeutic index of another therapy, namely, increase in the ratio between the therapeutic effect of the therapy to its undesired toxic side effects. The increase in therapeutic index may at times be used to advantage of increasing the dosage of the therapeutic agent, e.g. the dosage of the cytotoxic agent or radiation, without a concurrent increase in undesired toxic side effects.
- The tyrphostins according to the invention may be administered either in a single dose or may be given repetitively over a period of time, e.g. prior, during and after the treatment with a cytotoxic agent or irradiation.
- A preferred mode of administration of the tyrphostins to humans is intravenously, although by a proper formulation, they may also be administered by other administration modes, e.g. intramuscularly, intraperitoneally or orally.
- While the tyrphostin compositions will typically contain a single tyrphostin compound it is possible at times to include in the composition and or co-administer two or more tyrphostins which act together in a synergistic or additive manner to counter damages caused, e.g. by a therapeutic treatment.
- FIG. 1A is a graphic representation showing the mortality of mice treated with doxorubicin as compared to the mortality of mice receiving a single injection of AG1714 two hours before treatment with doxorubicin.
- FIG. 1B is a graphic representation showing, the mortality of mice treated with cisplatin as compared to the mortality of mice receiving a single injection of AG1714 two hours before treatment with cisplatin.
- FIG. 2 is a graphic representation showing the mortality of mice receiving 10 i.p. injections of doxorubicin (5 mg/kg) for a period of 21 days (
cumulative dose 50 mg/kg) as compared to the mortality of mice treated as above but receiving an i.p. injection of AG1714 (5 mg/kg) two hours prior to each doxorubicin injection. - FIG. 3 is a graphic representation showing the mortality of mice treated with cisplatin alone or with cisplatin and AG1801 over a period of ten days after cisplatin administration.
- FIG. 4 is a graphic representation showing the mortality of mice treated with doxorubicin alone or with tyrphostins and doxorubicin over a period of ten days after doxorubicin administration.
- FIG. 5 is a graphic representation showing the effect of a number of tyrphostins on the toxic effect of cisplatin in kidneys of treated mice. The toxic effect is measured by the level of creatinine detected in the serum of the treated mice, a high level of creatinine indicating kidney damage (nephrotoxicity).
- FIG. 6 is a graphic representation showing the level of creatinine (FIG. 6A) and blood urea nitrogcn (BUN) (FIG. 6B) (which are indicative of nephrotoxicity) in serum of mice receiving either cisplatin alone, AG1714 alone or a combination of cisplatin and AG1714. The levels of creatinine and BUN were compared to the levels of the same substances in serums of control mice receiving the vehicle only.
- FIG. 7 is a photograph showing histopathological analysis of kidneys (FIG. 7A-C) and small intestines (FIG. 7D-F) of mice administered with cisplatin alone or with the tyrphostin AG1714 prior to the administration of cisplatin. Final magnification ×400;
- FIG. 7A—kidneys of normal non-treated mice;
- FIG. 7B—kidneys of mice receiving cisplatin alone showing large proteinaceous plaques in the proximal tubules;
- FIG. 7C—kidneys of mice receiving AG1714 prior to cisplatin administration showing normal kidney structure;
- FIG. 7D—small intestines of non-treated mice;
- FIG. 7E—small intestine of mice receiving cisplatin alone showing severe necrosis and damage;
- FIG. 7F—a small intestine of mice treated with AG1714 prior to cisplatin administration showing normal small intestine structure;
- FIG. 8 is a graphic representation showing the level of two transaminases, Aspartic transaminasc (AST) and Alanine-transaminase (ALT) in serum of mice receiving an injection of anti-FAS antibody alone or in combination with the tyrphostin AG1801. High levels of the transaminases indicate anti-FAS antibody induced damage to the liver (hepatotoxicity);
- FIG. 9 is a graphic representation showing the level of two transaminases AST and ALT in serum of mice receiving an injection of anti-FAS antibody alone or in combination with the tyrphostin AG1714; High levels of the transaminases indicate anti-FAS antibody induced damage to the liver (hepatotoxicity);
- FIG. 10 is a graphic representation showing the level of AST and ALT in serum of mice treated with Con A alone or in combination with AG1714;
- FIG. 11 is a graphic representation showing the level of AST and ALT in serum of mice treated with TNF/GalN or in combination with the tyrphostin AG1714;
- FIG. 12 is a graphic representation showing the number of bone marrow nucleated cells (FIG. 12A) or the number of colony forming units (CFU) (FIG. 12B) in femur bone marrow of mice treated with doxorubicin alone, AG1714 along or with their combination;
- FIG. 13 is a graphic representation showing the number of nucleated cells in bone marrow of mice treated with doxorubicin alone or with AG1714 and doxorubicin:
- FIG. 13A shows the number of nucleated cells in bone marrow of the mice receiving different doses of doxorobucin;
- FIG. 13B shows the number of nucleated cells in bone marrow, of the treated mice at different periods of time after treatment with doxorubicin;
- FIG. 14 is a graphic representation showing the weight of the spleen (FIG. 14A) and thymus (FIG. 14B) of mice treated either with doxorubicin alone or with AG1714 prior to doxorubicin administration;
- FIG. 15 is a graphic representation showing the number of bone marrow nucleated cells in the femurs of mice treated with 5FU alone or with 5FU and AC1714;
- FIG. 16 is a graphic representation showing the number of bone marrow nucleated cells in the femurs of mice treated with mitomycin-C alone or with mitomycin-C and AG1714;
- FIG. 17 is a graphic representation showing the number of nucleated cells in bone marrow of mice treated with doxorubicin alone or with AG1801 at different doses prior to doxorubicin administration;
- FIG. 18 is a graphic representation showing the number of nucleated cells in bone marrow of irradiated mice (300R) and of mice treated with the tryphostin AG1714 before irradiation;
- FIG. 19 is a graphic representation showing the number of cells in bone marrow of irradiated mice (450R) and of mice treated with tyrphostin AG1714 before irradiation;
- FIG. 20 is a graphic representation showing the mortality of mice after lethal irradiation (800R) as compared to the mortality of mice treated with tyrphostin AG1714 prior to irradiation over a period of 23 days after irradiation;
- FIG. 21 is a graphic representation showing the weight of lungs of mice inoculated with MCA-105 fibrosarcoma cells (FIG. 21A), Lewis lung carcinoma cells (FIG. 21B) or B-16 melanoma cells (FIG. 21C) and treated with either cisplatin alone, AG1714 alone or with a combination of cisplatin and AG1714;
- FIG. 22 is a graphic representation showing the weight of nude mice bearing the SK-28 human melanoma tumors and treated with doxorubicin, AG1714 or their combination;
- FIG. 23 is a graphic representation showing the volume of the human ovary carcinoma tumor (OVCAR-3) in mice treated either with cisplatin alone, with AG1714 alone or with their combination;
- FIG. 24 is a graphic representation showing the volume of the OVCAR-3 tumor in mice receiving repetitive administration of the treatments described in FIG. 23 above;
- FIG. 25 is a graphic representation showing the weight of lungs in MCA-105 fibrosarcoma tumor bearing mice treated with cisplatin alone, AG1801 alone or a combination of both (FIG. 25A) or with doxorubicin alone, AG1801 alone or their combination (FIG. 25B);
- FIG. 26 is a graphic representation showing the weight of lungs of mice treated with cisplatin alone, AG1801 alone or a combination of both;
- FIG. 27 is a graphic representation showing the number of colony forming units (CFU) in cultures of bone marrow cells grown with or without various concentrations of AG1714;
- FIG. 28 is a graphic representation showing the viability of thymocytes grown with or without AG1714 at various periods of time after the addition of AG1714 to the cells;
- FIG. 29 is a graphic representation showing the number of beats per minute in cardiomyocyte cultures grown with or without AG1714 as an indication of the viability of the cells;
- FIG. 30 is a graphic representation showing the percent lysis measured by percent of specific51Cr release of target EL-4 cells by murine peritoneal exudate cytotoxic lymphocytes (PEL) in the presence or absence of AG1714.
- The preparation of several of the above novel compounds is exemplified in the following preparative examples. In all the examples below, the new compounds were synthesized by knoevenagel condensation of the aldehyde with malononitrile or the substituted amide.
-
- MS-m/e 307(M+, 50%), 290(M—HCN,63), 260(M—H—NO2,91), 201(M—NHCH2C6H5,15), 173 (M—CONHCH2C6H5,13), 155(22), 127(21), 105(100).
- 0.4 g, 2.65 mM, p-nitrobenzaldehyde, 0.57 g, 2.8 mM, N(cyano acetyl) 3-propyl phenyl amide (reference 9) and 40 mg β-alanine in 30 ml ethanol were refluxed for 4 hours. The solution was concentrated by evaporation, cooled and filtered to give 0.38 g, 43% yield, light-yellow solid, mp-98.
- NMR (CDCl3) δ 8.38(1H,S, vinyl), 8.35, 8.06(4H,ABq, JAB=8.6 Hz), 7.3(5H,m), 3.50(2H, J=8.0 Hz), 2.74(2H,t,J=8.0 Hz), 2.0 (2H,quintet, J=8.0 Hz).
-
- 170 mg, 1 mM, 3-fluoro 4-nitro benzaldehyde, 80 mg, 1.2 mM, malononitrile and 15 mg β-alanine were refluxed for 1 hour. Evaporation, trituration with hexane and filtering gave 202 mg, 93% yield, pink solid, mp-120°. NMR (CDCl3) δ 8.22(1H,m), 7.83(3H,m).
- MS-m/e 217(M+,100), 187(M—NO,78), 171(M—NO2,19), 159(M—NO—HCN—H,80), 151(M—NO2—HF,33), 144(M—NO2—HCN,71), 132(75), 124(M—NO2—HCN—HF,81).
- 0.4 g, 2.65 mM, 4-nitro benzaldehyde, 0.51 g, 2.8 mM, phenyl sulphonyl acetonitrile and 40 mg β-alanine in 30 ml ethanol were refluxed for 4 hours. Cooling, filtering and washing with ethanol gave 0.68 g, 82% yield, light yellow solid, mp-158°. NMR (CDCl3) δ 8.36(2H,d,J=8.6 Hz), 8.31(1H,S, vinyl), 8.07(4H,m), 7.70(3H,m).
- The biological and therapeutic effect of some of the compounds which may be used in the composition of the invention will now be exemplified in the following, non-limiting examples with occasional reference to the annexed figures.
- 6 weeks old female CD1 mice were divided into the following groups:
- i. Mice injected intraperitoneally (i.p.) with doxorubicin (20 mg/kg);
- ii. Mice injected i.p. with cisplatin (14 mg/kg);
- iii. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) two hours prior to the doxorubicin; and
- iv. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) two hours prior to receiving the cisplatin.
- As seen in FIG. 1, treatment of mice with AG1714 significantly reduced the mortality of the mice as compared to the mortality of mice receiving doxorubicin alone (p≦0.001) (FIG. 1A) or of mice receiving cisplatin alone (p≦0.005) (FIG. 1B).
- 6 weeks old female CD1 mice were divided into the following two groups:
- i. Mice receiving 10 i.p. injections of doxorubicin at a concentration of 5 mg/kg per each injection over 21 days (cumulative dose of 50 mg/kg,); and
- ii. Mice receiving 10 i.p. injections of doxorubicin at 5 mg/kg over 21 days with the addition of a single i.p. injection of AG1714 (5 mg/kg) two hours prior to each doxorubicin injection.
- Each group consisted of 10 mice and the % mortality in each group was tested as explained above.
- As seen in FIG. 2, the mortality of the mice receiving injections of AG1714 prior to each administration of doxorubicin was significantly reduced as compared to the high mortality of the mice receiving doxorubicin treatment alone.
- CD1 mice were divided into the following five groups:
- i. Mice receiving a single i.p. injection of 20 mg/kg of doxorubicin;
- ii. Mice receiving a single i.p. injection of 20 mg/kg of AG1714 and two hours later an i.p. injection of 20 mg/kg of doxorubicin;
- iii. Mice receiving a single i.p. injection of 20 mg/kg of AG1782 and two hours later an i.p. injection of 20 mg/kg of doxorubicin;
- iv. Mice receiving a single i.p. injection of 20 mg/kg of AG126 and two hours later an i.p. injection of 20 mg/kg of doxorubicin.
- The % mortality in each of the above groups was determined by scoring the number of dead mice every day until 10 days after injection.
- As seen in FIG. 10, in the group of mice receiving doxorubicin alone (i), 90% of the mice were dead within a week after injection. In the other groups of mice receiving the tyrphostins before the administration of doxorubicin, the % mortality was reduced to between 50% (iii) to only 10% (ii).
- Groups of CD1 mice, each comprising three mice were injected i.p. with a dose of 14 mg/kg of cisplatin. The mice in each of the groups except for one were injected with a single i.p. injection an tyrphostin at a dose of 10 mg/kg two hours prior to the injection of the cisplatin. In order to assess the toxic effect of cisplatin on the kidneys of the treated mice (nephrotoxicity), the level of creatinine was determined in the serum of each mouse four days after administration of the cisplatin using a commercial kit by Sigma.
- As seen in FIG. 5, the creatinine level of about 2 mg/dl detected in the serum of mice receiving cisplatin alone, indicates that there is about a 50% reduction in the kidney function of these mice. Against this, the level of creatinine measured in the serum of many of the mice receiving an injection of an tyrphostin before the cisplatin injection, was lower than the creatinine levels in the serum of mice receiving cisplatin alone. This indicates that injection of the tyrphostins prior to the cisplatin injection reduces the toxic effect of cisplatin on kidney function. The reducing effect on the nephrotoxicity of cisplatin varied between the different tyrphostins. For example, AG1824, AG1744, AG1751, AG1714, AG1823 AG1782, AG1801, markedly reduced the nephrotoxicity of cisplatin bringing the creatinine levels in the serum to those of control mice.
- CD1 female mice were injected either with cisplatin alone or with a single injection comprising either the tyrphostin AG1843 or AG1714 two hours before injection of cisplatin and the level of the creatinine in their serum was tested as explained above.
- As seen in Table 1 below and in agreement with the results of Example 10 above, cisplatin alone had a nephrotoxic effect on the mice as seen by their high serum creatinine levels (1.53). This toxic effect of cisplatin was significantly reduced (to between 0.45-0.70) by injecting the tyrphostins two hours before cisplatin injection. In this example, the effect of tyrphostin AG1843 administered at a low dose (5 mg/kg,) was more effective than the administration of a high dose (20 mg/kg) of the same tyrphostin.
TABLE 1 Groups Creatinine mg/dl (mean ± SD) Control (Cosolvent) 0.46 ± 0.01 Cisplatin 14 mg/kg i.p.1.53 ± 0.04 AG1843 5 mg/kg i.p. (−2 h) +0.45 ± 0.06 Cisplatin AG1843 20 mg/kg (−2 h) + 0.70 ± 0.14 Cisplatin AG1714 20 mg/kg (−2 h) + 0.58 ± 0.06 Cisplatin - CD1 mice were injected (i.p.) with cisplatin (14 mg/kg) or first with AG1714 (10 mg/kg) and two hours after with cisplatin as explained above. Mice in the control group received injections of the vehicle only (a stock solution of ethanol: chemaphore (50:50) diluted with saline). Four days after administration of the cisplatin, several parameters indicating nephrotoxicity and liver injury were measured in the serums of each of the
mice 4 days after cisplatin administration. The parameters showing nephrotoxicity of cisplatin were creatinine and blood urea nitrogen (BUN) and the parameters indicating damage to the liver were the hepatic transaminases alanine-transaminase (ALT) and aspartic transaminase (AST) measured by standard methods. Each group consisted of three mice and the results are shown as mean levels of the measured parameter±SD. - As seen in FIG. 6, administration of cisplatin alone to the mice resulted in elevated levels of creatinine (FIG. 6A) and BUN (FIG. 6B). Table 2 below shows that the levels of ALT and AST were also elevated in these mice. These results indicate both nephrotoxicity as well as damage to the liver of the mice as a result of the administration of cisplatin. As seen in FIG. 6 and Table 2, administration of AG1714 two hours before injection of the cisplatin, resulted in a reduced level of all four measured parameters to their normal level as measured in the control mice.
TABLE 2 Prevention of cisplatin - induced kidney and liver injury by AG1714 ALT AST Treatment u/L u/L Control (vehicle) 30 ± 4.7 58 ± 1.5 Cisplatin (14 mg/kg) 73.5 ± 2.1 209 ± 16.0 Cisplatin (14 mg/kg) + 36 ± 3.6 70 ± 14.0 AG1714 (20 mg/kg) - CD1 mice were injected with 14 mg/kg of cisplatin or first with a single i.p. injection of the tyrphostin AG1714 and two hours later an injection of 14 mg/kg of cisplatin. Histopathological analysis of the kidneys and small intestines of the non-treated and treated mice was performed using slices from formaline fixed tissues stained with hematoxylin eosin.
- As seen in FIG. 7, kidneys of mice receiving cisplatin alone showed large proteinaceous plaques in the proximal tubals (7B) as well as the appearance of granular material in the columnar epithel. Against this, kidneys of the mice receiving AG1714 injection prior to the cisplatin administration (7C) showed no damage and their structure was similar to that of control mice (7A).
- As also seen in FIG. 7, the small intestine of mice receiving cisplatin alone (7E) showed severe necrosis and disintegration of the columnar intestinal epithelial cells as compared to the small intestines of mice receiving AG1714 prior to the cisplatin administration (7F) which showed a normal structure similar to that seen in the small intestine of non-treated mice (7D).
- In order to test the protective effect of AG1714 against doxorubicin-induced cardiotoxicity, 7 day primary rat cardiomyocytes cultures were prepared according to a standard procedure (described in: In vitro Toxicology, Model System and Methods, Eds. C. McQueen, Telford Press New Jersey, 1990, pg. 163, Primary cultures of neonatal rat myocardial cells, and Kessler-Icekson, G.,J. Mol. Cell Cardiol, 20:649-755, 1988).
- The cardiomyocyte cultures were divided into the following four groups receiving:
- i. Vehicle only (control);
- ii. AG1714 as a final concentration of 20 μM;
- iii. Cells receiving doxorubicin at a concentration of 10 μM; and
- iv. Cells receiving AG1714 at a final concentration of 20 μM followed one hour later by the addition of doxorubicin (10 μM).
- The rate of beats of clusters of cardiomyocytes (“mini-hearts”) was determined 24 hours after beginning of incubation.
- As seen in Table 3, in the cell cultures incubated with doxorubicin alone, the number of beats per minute was significantly reduced to about 20% of that of the control cultures incubated with the vehicle only. Against this, in cultures incubated with doxorubicin together with AG1714, the number of beats per minute was similar to the number of beats per minute in the control cultures. Similar results (not shown) were seen in the
above cardiomyocyte cultures 16 hours and 40 hours after incubation. Thus, incubation of the cultures with AG1714 one hour before the addition of doxorubicin prevented the cardiotoxic effect of doxorubicin on the cell cultures.TABLE 3 Protective effect of AG1714 against Doxorubicin - induced cardiotoxicity, in vitro Cellular beating Treatment (beats/min) Control (vehicle) 78 ± 2.0 AG1714 (20 uM) 68 ± 2.2 Doxorubicin (10 uM) 15 ± 1.3 Doxorubicin + 62 ± 2.6 AG1714 - The FAS antigen is a cell surface protein belonging to the two factor/nerve (growth factor receptor family and have been shown to mediate apoptosis (Itoh, N. et al.,Cell, 66:233-243(1991)). Intraperitoneal administration of an anti-FAS antibody into mice was shown to cause severe damage of the liver by apoptosis.
- In order to test the effect of the tyrphostin AG1801 and AG1714 on the anti-FAS antibody induced hepatotoxicity, Balb/C mice were injected i.p. either with AG1801 (5 mg/kg) or with AG1714 (5 mg/kg) and two hours later with an i.p. injection of an anti-FAS antibody at a dose of 5 μg/mouse. Another group of mice received only an injection of anti-FAS antibody with no prior treatment with the tyrphostins. Five hours after injection of the anti-FAS antibody, the animals were sacrificed and the level of two transaminases AST and ALT in the serum of the sacrificed mice was determined: a high level of these transaminases indicating hepatotoxicity (Ogasaware, J., et al.,Nature, 364:806-809, 1993).
- As seen in FIGS. 8 and 9, the level of AST and ALT in the serum of mice treated with the anti-FAS antibody alone was very high indicating FAS antibody induced hepatotoxicity.
- Against this, the level of the two transaminases AST and ALT in serum of mice which were treated with AG1801 (FIG. 8) or with AG1714 (FIG. 9) prior to the anti-FAS injection was significantly lower. Thus, administration of the tyrphostins to mice results in their protection against hepatotoxicity induced by the anti-FAS antibody.
- T-cell mediated hepatotoxicity is a complication of various disorders and diseases such as Hepatitis B virus infection. Such hepatotoxicity can be induced by injection of Conavalin A (Con A). The effect of AG1714 on Con A induced hepatotoxicity on mice was determined in the following way (see Tiegs, G. et al.,J. Clin. Invest., 90:196-203, 1992).
- CD1 mice were divided into the following groups:
- i. Mice receiving injection of the vehicle only (control);
- ii. Mice receiving i.p. injection of AG1714 (10 mg/kg);
- iii. Mice receiving an i.v. injection of Con A (35 mg/mouse); and
- iv. Mice receiving, an i.p. injection of AG1714 (10 mg/kg) and two hours later an i.v. injection of Con A (35 mg/mouse).
- 6 hours after injection of Con A to the mice, serum levels of the liver enzymes AST and ALT of the treated mice were determined as explained above. Increase of serum levels of these enzymes reflect liver injury.
- As seen in FIG. 10, while administration of AG1714 alone had no effect on the mice, injection of Con A caused significant hepatotoxicity in the mice. Administration of AG1714 prior to Con A administration significantly reduced the Con A induced hepatotoxicity in these mice.
- It is today known that liver damage may be induced by various immune mechanisms such as cytokines as well as by a variety of other agents known to exert an apoptotic effect (e.g. alcohol or paracetemol). A model for such liver injury induced by apoptosis was developed in which the hepatic damage is induced in vivo by the injection of galactosamine and TNF-α (see Leist, M., et al.,J. Immunol., 153:1778-1783, 1994).
- The effect of AG1714 on TNF-induced liver damage in mice was determined as follows.
- Mice were divided into the following four groups:
- i. Mice receiving an injection of the vehicle alone;
- ii. Mice receiving 1 i.p. injection of AG1714 (10 mg/kg);
- iii. Mice receiving an i.v. injection of human TNF-α (0.25 μg/mouse) in combination with galactosamine (GaIN) (18 ml/mouse, i.p.); and
- iv. Mice receiving the treatment of group iii above together with an injection of AG1714 (10 mg/kg) injected i.p. two hours prior to TNF/GaIN injection. 7 hours after injection of the TNF/GaIN, the serum levels of the liver enzymes AST and ALT in the serum of the various treated mice was determined as described above.
- As can be seen in FIG. 11, injection of AG1714 prior to the administration of TNF/GaIN to the mice significantly reduced the hepatoxicity induced by the TNF/GaIN administration. The tyrphostins may therefore be useful in the reduction of liver damage induced by various immune mechanisms.
- CD1 mice were divided into the following groups:
- i. Mice receiving an i.p. injection of doxorubicin (10 mg/kg) alone;
- ii. Mice receiving an i.p. injection of AG1714 (20 mg/kg) and two hours later an i.p. injection of doxorubicin (10 mg/kg); and
- iii. Mice receiving one injection of the vehicle and two hours later an i.p. injection of doxorubicin (10 mg/kg).
- 3 days later, the number of bone marrow nucleated cells and colony forming units (CFU) in the femurs of the treated mice was determined (Nikerich, D. A., et al.,J. Immunopharmacol., 8:299-313, 1986). Each group contained 3 mice and the results arc expressed as a means±SD.
- As seen in FIG. 12, injection of doxorubicin to mice resulted 3 days later in myelotoxicity as manifested by 47% reduction in the number of nucleated cells (FIG. 12A) and 55% reduction in CFU (FIG. 12B). Mice who were pretreated with AG1714 two hours prior to doxorubicin injection were fully protected against its myelotoxicity effects.
- The effect of AG1714 on myelotoxicity induced by doxorubicin at different doses was investigated. Mice were treated as described in Example 18 above. The number of femur nucleated bone marrow cells in the treated mice was determined three days (FIG. 13A) and at various times (FIG. 13B) post doxorubicin administration.
- As seen in FIG. 13A, administration of doxorubicin to mice at a concentration of 10 mg/kg and 15 mg/kg induced myelotoxicity in the treated mice. Pretreatment with AG1714 reduced the doxorubicin induced myelotoxicity significantly.
- As seen in FIG. 13B, pretreatment of mice administered with doxorubicin with AG1714, resulted also in a rapid recovery of bone marrow cells after doxorubicin administration. 5 days after treatment with doxorubicin (15 mg/kg) alone, the number of bone marrow cells in the femurs of the treated mice was still significantly reduced. Pretreatment of the mice with AG1714 prior to the doxorubicin administration, fully reconstituted their bone marrow at that time.
- As seen in FIG. 14 below, the administration of doxorubicin alone caused a significant reduction in the weight of spleens (FIG. 14A) and thymuses (FIG. 14B) of the mice. This myelotoxic and lymphotoxic effect of doxorubicin was significantly reduced by the administration of AG1714 to the mice two hours before administration of the doxorubicin.
- CD1 mice were injected with a single i.p. injection of cyclophosphamide at a dose of 50 mg/kg and divided into the following groups;
- i. Mice receiving a single i.p. injection of the vehicle only two hours before administration of the cyclophosphamide;
- ii. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) two hours before cyclophosphamide;
- iii. Mice receiving a single i.p. injection of AG1801 (2.5 mg/k,) two hours before cyclophosphamide administration.
- 72 hours after cyclophosphamide administration the mice were sacrificed and the nucleated cells in the bone marrow, spleen and thymus of the mice were counted. Each experimental group consisted of three mice and the results shown are the mean number of cells in a group±SD.
- As seen in Table 4A and B, administration of cyclophosphamide caused a significant reduction in the number of nucleated cells in the bone marrow, spleen and thymus indicating myelotoxic and lymphotoxic effect of cyclophosphamide. Administration of the tyrphostins AG1714 or AG1801 prior to the administration of cyclophosphamide, resulted in a reduction in the myelotoxic and lymphotoxic effect of cyclophosphamide in the above three organs. The number of nucleated cells in these organs was higher than in organs of mice receiving cyclophosphamide alone although the level of the nucleated cells in the bone marrow, spleen and thymus of the mice treated with the tyrphostins did not reach control level
TABLE 4a and b AG1714 and AG1801 prevent Cyclophosphamide - induced myelotoxicity and lymphotysis Nucleated cells in Spleen Thymus Treatment bone marrow (× 106) (mg) (mg) AG1714 (20 mg/kg) Vehicle − + − + − + 17.3 ± 1.33 17.9 ± 1.1 109 ± 20.0 112 ± 11.3 75 ± 4.0 71 ± 9.8 Cyclophosphamide 6.2 ± 0.31 11.2 ± 0.6 52 ± 2.5 87 ± 2.0 39 ± 6.1 57 ± 3.6 (50 mg/kg) AG 1801 (2.5 mg/kg) Vehicle − + − + − + 17.3 ± 18.6 ± 1.0 109 ± 20.0 97 ± 1.52 75 ± 4.0 74 ± 7.9 1.33 Cyclophosphamide 6.2 ± 0.31 10.9 ± 0.9 52 ± 2.5 69 ± 0.58 39 ± 6.1 57 ± 5.6 (50 mg/kg) - CD1 female mice were divided into the following groups:
- i. A control group receiving a single i.p. injection of the vehicle only (co-solvent: propylene carbonate-cremophor-saline);
- ii. Mice receiving a single i.p. injection of 5-fluorouracil (5 FU) at a dose of 80 mg/kg;
- iii. Mice receiving a single i.p. injection of AG1714 at a dose of 20 mg/kg;
- iv. Mice receiving a single i.p. injection of AG1801 at a dose of 2.5 mg/kg;
- v. Mice receiving a single i.p. injection of AG1843 at a dose of 5 mg/kg;
- vi. Mice receiving a single i.p. injection of AG1714 (20 mg/kg and two hours later a single i.p. injection of 5 FU (80 mg/kg);
- vii. Mice receiving a single i.p. injection of AG1801 (2.5 mg/kg) and two hours later a single i.p. injection of 5 FU (80 mg/kg); and
- viii. Mice receiving a single i.p. injection of AG1843 (5 mg/kg) and two hours later a single i.p. injection of 5 FU (80 mg/kg).
- Five days after the administration of 5 FU to the mice, the mice were sacrificed and the number of nucleated cells in the bone marrow of one femur, were counted. Each group of mice consisted of two or three mice and the results shown are the mean number of cells counted±SD.
- As seen in FIG. 15, administration of 5 FU to the mice resulted in a decrease in the number of nucleated cells in the bone marrow of these mice. The administration of the AG1714 before 5 FU administration to the mice, resulted in a significantly lower reduction in the number of cells in the bone marrow. Thus the AG1714 reduced the myelotoxic effect of 5 FU in these mice.
- CD1 female mice were divided into the following groups:
- i. A control group receiving a single i.p. injection of the vehicle only (co-solvent: propylene carbonate-cremophor-saline);
- ii. Mice receiving a single i.p. injection of mitomycin-C at a dose of 2 mg/kg;
- iii. Mice receiving a single i.p. injection of AG1714 at a dose of 20 mg/kg;
- iv. Mice receiving a single i.p. injection of AG1714 (20 mg/kg) and two hours later a single i.p. injection of mitomycin-C (2 mg/kg);
- As described in Example 22 above, five days after the administration of mitomycin-C to the mice, the mice were sacrificed and the number of nucleated cells in the bone marrow of one femur, were counted. Each group of mice consisted of two or three mice and the results shown are the mean number of cells counted±SD.
- As seen in FIG. 16, mice receiving mitomycin-C alone showed a very low count of nucleated cells in their bone marrow. While administration of AG1714 alone had no effect on the mice, its administration prior to the administration of mitomycin-C to the mice resulted in a reduction in the myelotoxic effect of the mitomycin-C in these mice and provided almost full protection from the harmful effects of the mitomycin-C bringing the nucleated cell count in the bone marrow of these mice to the level of control mice receiving the cosolvent only.
- The effect of various doses of AG1801 against doxorubicin induced myelotoxicity in mice was determined. CD1 mice were divided into five groups:
- i. Mice receiving the vehicle alone;
- ii. Mice receiving doxorubicin (10 mg/kg) alone;
- iii. Mice receiving an i.p. injection of AG1801 (0.5 mg/kg) two hours prior to doxorubicin administration;
- iv. Mice receiving an i.p. injection of AG1801 (1 mg/kg) two hours prior to doxorubicin administration; and
- v. Mice receiving an i.p. injection of AG1801 (2 mg/kg) two hours prior to doxorubicin administration.
- Three days after doxorubicin administrations the mice were sacrificed and the number of nucleated cells in bone marrow was determined as described above.
- As seen in FIG. 17, administration of AG1801 to the mice had a protective effect against doxorubicin induced myelotoxicity which was dose dependent.
- In order to test the protective activity of the tyrphostin AG1714 in radiated mice, CD1 mice irradiated with a radiation dose of 300R using a cobalt source were divided into two groups:
- i. Mice receiving no further treatment; and
- ii. Mice receiving a single i.p. injection of the tyrphostin AG1714 at a dose of 20 mg/kg, two hours before irradiation.
- A third group of mice received only a single injection of AG1714 (20 mg/kg) and a fourth group of mice served as control mice which were not treated.
- At different periods of time after irradiation, mice were sacrificed and the number of cells in the bone marrow of one femur were counted.
- As seen in FIG. 18, irradiation of the mice with 300R caused a decrease in the number of cells in the bone marrow of these mice as compared to untreated mice or mice treated only with AG1714. Reconstitution of cells in the bone marrow of the irradiated mice began about five days after their radiation. Treatment of the irradiated mice with AG1714 prevented the decrease in the number of cells in the bone marrow of the irradiated mice and caused a very significant enhancement of the number of cells in their bone marrow. Thus, the tyrphostin AG1714 has a protective effect against myelotoxicity caused by irradiation.
- The protective effect of the tyrphostin AG1714 against myelotoxicity caused by a high dose irradiation (450R) was tested as described in Example 25 above except that the dose of irradiation was 450R instead of 300R.
- As seen in FIG. 19, the number of cells in the bone marrow of mice irradiated with 450R was significantly reduced five days after radiation indicating a severe myelotoxic effect of the irradiation on these mice. Five days after irradiation reconstitution of the number of cells in the bone marrow began but 18 days after radiation, the number of cells in the bone marrow of the irradiated mice still remained significantly lower than the number of cells in the bone marrow of non-treated mice or mice receiving AG1714 alone. In the bone marrow of mice receiving AG1714 before their irradiation, myelotoxic effect was also seen until five days after radiation. However, after five days, a significant reconstitution was seen in the number of cells in the bone marrow of these mice and 18 days after irradiation, the number of cells in the bone marrow of the irradiated mice receiving AG1714 was higher than the number of cells in the control mice. Administration of AG1714 thus enhance the reconstitution of the number of cells in the bone marrow of mice irradiated by high dose irradiation.
- CD1 mice were irradiated with a lethal 800R dose using a cobalt source, and divided into two groups:
- i. Mice receiving irradiation only; and
- ii. Mice receiving a single i.p. injection of AG1714 at a dose of 20 mg/kg one hour before irradiation.
- Each croup of mice consisted of 10 mice and the % mortality in each group was tested by scoring the number of dead mice each day after irradiation.
- As seen in FIG. 20, in the group of mice receiving an 800R irradiation, mortality of the mice began 10 days after irradiation and the % mortality in this group reached the rate of 80% 23 days after their irradiation. Against this, the % mortality in the group of mice receiving AG1714 before their irradiation was significantly reduced to 20
% mortality 20 days after irradiation. - The mortality in both groups did not change further until 50 days after irradiation.
- The effect of AG1714 on the anti-tumor effect of chemotherapy was determined using a variety of experimental tumor models in mice.
- 2×105/mouse MCA-105 fibrosarcoma cells or Lewis Lung carcinoma cells and 5×104/mouse B-16 melanoma cells were injected into the tail vein of C57BL mice.
- Cisplatin (4 mg/kg) was injected i.p. 4 days after tumor inoculation. AG1714 (20 mg/kg) or vehicle was injected i.p. 2 hours prior to cisplatin. Twenty-four days after tumor inoculation, mice were sacrificed, lungs weighed and the number of metastases were scored. Each group contained 5 mice and the results are expressed as the means lungs' weights±SE.
- As seen in FIG. 21A, cisplatin markedly inhibited the growth of MCA-105 fibrosarcoma. AG1714 by itself had a small anti-tumor effect. Combined treatment with AG1714 and cisplatin was as effective as cisplatin alone, in suppression of the growth of the established lung metastases of MCA-105. Cisplatin and AG1714 by themselves had a partial anti-tumor effect against Lewis lung carcinoma. Combined treatment with AG1714 and cisplatin was more effective than cisplatin also in suppression of the growth of established lung metastases of this tumor (FIG. 21B).
- Cisplatin (4 mg/kg) or AG1714 (20) mg/kg) alone were not effective against established lung metastases of B-16 melanoma (FIG. 21C). Combined treatment with these agents was more effective than treatment with each agent alone.
- The effect of doxorubicin and AG1714 on SK-28 human melanoma tumor xenografts in nude mice was determined as follows:
- CD1 athymic mice (nu/nu) were inoculated i.v. with 4×105/mouse SK-28 human melanoma. Doxorubicin (4 mg/kg) was injected i.p. 4 days after tumor inoculation. AG1714 (20 mg/kg) or vehicle were injected 2 hours prior to doxorubicin. The weights of the treated mice lungs and number of metastases in the lungs were determined 24 days after tumor inoculation. Each group contained 5 mice and the results are expressed as means±SE.
- As seen in FIG. 22, doxorubicin markedly suppressed the growth of the SK-28 tumor whereas AG1714 by itself had a small anti-tumor effect. Pretreatment with AG1714 did not impair the effect of doxorubicin alone in the suppression of the growth of this tumor.
-
- Each group contained 5 mice and the results are expressed as the means±SE.
- As seen in FIG. 23, cisplatin had a marked anti-tumor effect in the mouse bearing OVCAR-3 tumors whereas AG1714 itself was less effective. Administration of AG:1714 did not impair the chemotherapeutic effect of cisplatin.
- As seen in FIG. 24, the difference in the diameter of the tumor volume of tumors in mice receiving repeated injections of cisplatin and AG1714 as compared to the volume of tumors in mice receiving repeated injections of cisplatin alone or repeated injections of AG1714 alone.
- The effect of AG1714 on high dose doxorubicin efficacy was measured by determining the mortality of B-16 melanoma bearing mice and the number of metastases in their lung's or the lung weight.
- Mice were injected i.v. with 2×105 B-16 melanoma cells and 4 days after tumor inoculation each mouse received a single i.p. injection of doxorubicin (4 mg/kg, or 8 mg/kg). Two hours prior to the doxorubicin injection, each mouse was injected i.p. with AG1714 at a dose of 20 mg/kg.
- As seen in Table 5A and B showing two experiments carried out as explained above, administration of low dose doxorubicin resulted in low mortality of the mice and in a significant therapeutic effect. High dose administration of doxorubicin resulted in a much more significant therapeutic effect but resulted in a high mortality rate of the treated mice. AG1714 administered alone showed some therapeutic effect in itself. The combined administration of doxorubicin at a high dose together with AG1714 resulted in the high therapeutic effect of the high doxorubicin, however, the mortality of the mice were significantly reduced.
TABLE 5 Effect of AG1714 on high dose doxorubicin efficacy and mortality in B-16 melanoma bearing mice A. No. of lungs' metastases Mortality Treatment (+SD) (dead/total) Vehicle 29 ± 9 0/4 AG1714 (20 mg/kg) 16 ± 5 0/4 Doxoruhicin (4 mg/kg) 7 ± 4 0/4 Doxorubicin (4 mg/kg) + 7 ± 6 0/4 AG1714 (20 mg/kg) Doxorubicin (8 mg/kg) 1 3/4 (75%) Doxorubicin (8 mg/kg) + 2 ± 1 0/4 AG1714 (20 mg/kg) No tumor — 0/4 B. Lungs' weight Mortality Treatment (mg + SEM) (dead/total) Vehicle 976 ± 142 0/6 AG1714 (20 mg/kg) 870 ± 178 0/6 Doxorubicin (4 mg/kg) 306 ± 12 0/6 Doxorubicin (4 mg/kg) + 303 ± 28 0/6 AG1714 (20 mg/kg) Doxorubicin (8 mg/kg) — 7/8 (88%) Doxorubicin (8 mg/kg) + 246 ± 10 2/8 (25%) AG1714 (20 mg/kg) No tumor 232 ± 12 0/3 - Thus the combined administration of AG1714 together with doxorubicin resulted in the intensification of the chemotherapeutic effect of doxorubicin. The significant therapeutic effect of the high dose doxorubicin administered with AG1714 could be achieved while the high mortality rate of the high dose doxorubicin was neutralized by the combined administration.
- Such an intensification effect could also be seen in mice bearing MCA-105 fibrosarcoma tumors and treated with either doxorubicin alone (Table 6A) or cisplatin alone (Table 6B) or with a combination of each of the above with AG1714.
TABLE 6 Effect of AG1714 on high dose doxorubicin efficacy and mortality in MCA-105 fibrosarcoma bearing mice Lungs' weight Mortality Treatment (mg + SEM) (dead/total) A. Vehicle 908 ± 107 0/8 AG1714 (20 mg/kg) 632 ± 74 0/6 Doxorubicin (4 mg/kg) 47 ± 119 0/5 Doxorubicin (4 mg/kg) + 494 ± 137 0/5 AG1714 (20 mg/kg) Doxorubicin (8 mg/kg) 170 ± 4 5/8 (62.5%) Doxorubicin (8 mg/kg) + 172 ± 6 2/8 AG1714 (20 mg/kg) (25%) No tumor 161 ± 12 0/4 B. Vehicle 982 ± 102 0/6 AG1714 (20 mg/kg) 656 ± 127 0/6 Doxorubicin (4 mg/kg) 420 ± 69 0/6 Doxorubicin (4 mg/kg) + 216 ± 33 0/6 AG1714 (20 mg/kg) Doxorubicin (8 mg/kg) 186 ± 16 5/7 (71%) Doxorubicin (8 mg/kg) + 167 ± 5 2/6 AG1714 (20 mg/kg) (33%) No tumor 161 ± 6 0/6 - The effect of AG1801 on the anti-metastatic activity of cisplatin on established lung metastases of MICA-105 fibrosarcoma bearing, mice was determined as follows:
- C57BL mice were divided into the following groups:
- i. Mice injected i.v. at the age of 6 weeks with 2×105 fibrosarcoma MCA105 cells and 4 days' later, receiving, an injection comprising the vehicle only;
- ii. Mice injected i.v. at the age of 6 weeks with 2×105 fibrosarcoma MCA105 cells and 4 days' later, injected with 10 mg/kg, of cisplatin,
- iii. Mice injected i.v. at the age, of 6 weeks with 2×105 fibrosarcorna MCA105 cells and 4 days' later, injected with 10 mg/kg of, doxorubicin;
- iv. Mice injected i.v. at the age of 6 weeks with 2×105 fibrosarcoma MCA105 cells and 4 days' later, injected with 5 mg/kg of AG1801;
- v. Mice injected i.v. at the age of 6 weeks with 2×105 fibrosarcoma MCA-105 cells and 4 days' later, injected with 5 mg/kg of AG1801 and 2 hours' later, with 10 mg/kg of cisplatin;
- vi. Mice injected i.v. at the age of 6 weeks with 2×105 fibrosarcoma MCA-105 cells and 4 days' later, injected with 5 mg/kg of AG1801 and 2 hours' later, with 10 mg/kg of doxorubicin; and
- vii. Non treated C57BL mice.
- As seen in FIG. 25A and 25B, the weight of the lungs of the tumor bearing mice were significantly higher than that of the control mice. While injection of AG1801 alone had no affect, the injection of cisplatin (FIG. 25A) or doxorubicin (FIG. 25B) reduced the weight of the mice's lungs to a weight similar to that of control non tumor bearing mice. The combined injection of cisplatin and AG1801 (FIG. 25A) and the combined injection of doxorubicin and AG1801 (FIG. 25B) resulted in reduction of tumor load in the lungs of the mice similar to the reduction in the tumor load of mice receiving the cisplatin alone.
- The results of the above four examples clearly show that administration of tyrphostins to tumor bearing, mice together with cisplatin does not affect the antitumor affect of the cisplatin and in some cases eve;<increases it.
- The effect of cisplatin and AG1801 on SK-28 human melanoma tumor xenografts in nude mice was determined as explained in Example 29 above.
- As seen in FIG. 26, the administration of cisplatin alone reduced the weight of the lungs of the tumor bearing mice to an extent while administration of AG1801 had no therapeutic effect in itself. Combined administration of AG1801 with cisplatin significantly reduced the rate of lungs of the treated mice and thus the administration of AG1801 prior to cisplatin administration enhanced its therapeutic effect.
- The above examples clearly show that administration of tyrphostins to tumor bearing mice together with cisplatin or doxorubicin does not impair the anti-tumor effect of the therapeutic agents and in some cases even increases it. Therefore the tyrphostins could be useful in potentiating and intensifying the chemotherapeutic effect of such agents.
- Murine bone marrow nucleated cells were prepared by gradient centrifugation on histopaque. The cells were then divided into two groups:
- i. Cells incubated for one hour in growth medium alone (control);
- ii: Cells incubated for one hour in growth medium with the addition of various concentrations (5 μM; 10 μM or 20 μM) of the tyrphostin AG1714.
- Cells were then plated on semi-solid agar and the number of colony forming units (CFU) was determined after a 14 day incubation period (see: Nikerich et al., supra, 1986).
- As seen in FIG. 27, the plating, efficiency (determined by the number of CFU per 105 nucleated cells) of the cultures to which AG1714 was added was significantly enhanced as compared to that of the cells grown in growth medium alone. Thus, the tyrphostin AG1714 enables longer preservation of bone marrow cell culture.
- Thymocytes were prepared from thymuses of young CD1 mice at a concentration of 3×106 cell/ml in RPNI1640 growth medium containing 5% FCS. The cells were divided into two groups:
- i. A Cells grown in the presence of growth medium alone; and
- ii. Cells grown in growth medium with the addition of AG1714.
- The cell viability of the thymocytes in each of the above cultures was determined using the trypsin blue exclusion test at various periods of time after the addition of AG1714 to the cells.
- As seen in FIG. 28, addition of AG1714 to the thymocytes in culture significantly enhanced their viability.
- Primary rat myocyte cultures were prepared from rats as described in Kessler-Iccksan, G.,J. Mol. Cell. Cardiol., 20:649-755, 1988. Cardiomyocytes were grown in culture for seven days and then the cultures were divided into two groups:
- i. Cultures grown in growth culture alone;
- ii. Cultures grown in growth culture with the addition of 20 μM of the tyrphostin AG 1714.
- The number of beats per minute of the myocyte clusters in each culture was determined 16 hours and 40 hours after the addition of the tyrphostins to the cells.
- As seen in FIG. 29, the number of beats per minute in the cardiomyocyte cultures to which the tyrphostin AG1714 was added were significantly higher than the number of beats per minute in the cultures grown in the growth medium alone. AG1714 enhanced the viability of the cardiomyocytes in culture.
- In order to study the toxic effects of the tyrphostins AG1714 and AG1801, the tyrphostins were injected to
ICR mice 3 times a week over a period of five weeks. Each injection contains 20 mls. of the tyrphostins which was prepared in the vehicle propylene carbonate:cremophore (40/60) diluted 1:20 with saline/bicarbonate. - In order to test the toxic effect of the cumulative administration of the tyrphostins, various parameters of the injected mice were determined including their weight, weight of their internal organs (thymus, spleen, kidney), full blood chemistry, number of bone marrow cells, etc.
- As seen in Table 7 below, injection of the tyrphostins AG1714 and AG1801 caused no significant changes in the parameters tested in the injected mice as compared to the same parameters in control mice injected with saline or the vehicle only. Therefore, no toxic effects of the tyrphostins were apparent following their cumulative administration to mice. In addition, injection of the tyrphostins caused no mortality of the mice.
TABLE 7 Subchronic intraperitoneal administration of AG1714 and AG1801 (ICR female mice, injection 3 times a week, 5 weeks)Control 1Control 2AG1714 Ag1801 Saline Vehicle 20 mg/kg × 15 5 mg/kg × 15 Weight (g) 29.3 ± 3.1 28.6 ± 2.3 29.1 ± 1.7 Thymus (mg) 50.2 ± 7.7 53.8 ± 12.3 57 ± 9.3 Spleen (mg) 118 ± 27 136 ± 16 119 ± 19.6 Kidney (mg) 176 ± 21 162 ± 12 164 ± 9.8 Leukoc. (k/ul) 6.1 ± 2.3 5.5 ± 0.98 4.9 ± 2.3 6.8 ± 3.3 Lymph. (%) 88.1 ± 2.35 83.3 ± 4.12 81.5 ± 2.35 80.4 ± 6.1 Neutr. (%) 4.2 ± 1.4 4.2 ± 1.2 5.3 ± 1.2 Monoc. (%) 10.6 ± 2.6 11.9 ± 1.3 12.3 ± 5.2 Eosin.. (%) 0.2 ± 0.1 0.1 ± 0.05 0.3 ± 0.23 Basoph. (%) 0.22 ± 0.08 0.24 ± 0.11 0.3 ± 0.07 RBC (M/ul) 8.4 ± 0.33 9.0 ± 0.33 8.4 ± 0.3 HGB (g/dl) 14.0 ± 2.5 14.2 ± 0.5 14.9 ± 0.56 14.5 ± 0.67 PLT (K/ul) 1236 ± 176 1229 ± 12.7 1475 ± 252 1309 ± 304 Glucose (mg/dl) 147 ± 11.3 177 ± 24 144 ± 17 177 ± 20.5 BUN (mg/dl) 22 ± 4.4 21 ± 2.9 25.2 ± 3.3 24.2 ± 2.2 Creatinine (mg/dl) 0.4 ± 0.0 0.42 ± 0.04 0.46 ± 0.05 0.42 ± 0.04 Total Prot. (g/dl) 5.4 ± 0.17 5.6 ± 0.2 5.8 ± 0.2 5.6 ± 0.08 Albumin (g/dl) 3.1 ± 0.0 3.1 ± 0.09 3.2 ± 0.13 3.1 ± 0.07 Calcium (mg/dl) 9.9 ± 0.4 9.9 ± 0.26 9.9 ± 0.3 9.8 ± 0.36 In. Phosph. (mg/dl) 8.5 ± 0.7 8.0 ± 0.75 8.4 ± 0.43 7.9 ± 1.1 Uric acid (mg/dl) 1.1 ± 0.21 2.0 ± 0.44 1.8 ± 0.18 2.0 ± 0.36 Total Bilirub. (mg/dl) 0.23 ± 0.06 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 Alk. Phosph. (U/l) 110 ± 23.8 79 ± 17 67 ± 12.8 69.6 ± 0.26 LHD (U/l) 545 ± 157 996 ± 235 960 ± 226 972 ± 238 GOT (U/l) 67 ± 11 71.4 ± 6.5 70 ± 18 68 ± 12 GPT (U/l) 30 ± 4.6 28.8 ± 3.1 25.6 ± 4.2 28 ± 5.5 CPK (U/l) 461 ± 179 604 ± 115 659 ± 486 582 ± 127 Amylase (U/l) 2451 ± 176 2211 ± 352 2392 ± 230 2169 ± 222 Cholester. (mg/dl) 115 ± 25 98.8 ± 17.5 99 ± 5.7 90 ± 6.1 Triglycer. (mg/dl) 216 ± 84 125 ± 17.9 155 ± 54 138 ± 50 Nuclear BM cells × 106 16.3 ± 0.7 15.2 ± 2.0 18.6 ± 3.6 16.5 ± 0.87 Colonies (in femur) 12790 ± 1620 17600 ± 2590 15690 ± 2040 Clusters (in femur) 8170 ± 697 15000 ± 2140 13410 ± 1740 - Murine peritoneal exudate cytotoxic lymphocytes (PEL) capable of specific lysis of EL-4 cells were prepared and tested as described in Lavy, R. et al.,J. Immunol. 154:5039-5048, 1995. The EL-4 cells were divided into cells which were incubated with PELs alone, cells which were incubated with AG1714 (20 μM) and then with PELs and cells which were incubated with AG1714 (50 μM) and then with PELs. The lysis of the target EL-4 cells was determined using the specific 51Cr release assay.
- As seen in FIG. 30, addition of AG1714 reduced the specific cytotoxic activity of PELs against the target EL-4 cells. The inhibitive effect of AG1714 was dose dependent.
- The above results indicate that tyrphostins may be useful for reducing immune mediated rejection of transplants, in cases of autoimmunity and in conditions involving specific immune activity against cells (e.g. anti-CD4 cells such as in the case of AIDS).
- One of the main complications of an inflammatory reaction in an individual is the development of septic shock which results from over effects of the immune reaction which is mediated mainly by cytokines such as TNF and IL-1. The involvement of tyrphostins in TNF and IL-1 related immune responses was determined as follows:
- A. Incubation of mouse fibroblastic cells with TNF-α result in apoptosis of these cells. In order to test the effect of tyrphostins on the TNF-α-induced apoptosis of the cells, A9 mouse fibroblastic cells were incubated for two hours with cycloheximide (50 μg/ml) after which the various tyrphostins were added at a final concentration of 20 μM except AG1801 that was added at the final concentration of 5 μM. Following one hour incubation with the tyrphostins, TNF-α was added to the cells at a concentration of 0.2 ng/ml and the cells were incubated for an additional ten hours. At the end of ten hours, the cell cultures were analyzed by FACS using propidium iodide and the extent of apoptosis in each of the cell cultures (seen as DNA fragmentation) was determined (see Novogrodsky, A., et al,Science, 264:1319-1322, 1994).
- As seen in Table 8 below, addition of the various tyrphostins to the mouse fibroblastic cells incubated with TNF, reduced the apoptopic effect of TNF significantly. The extent of the reduction of the apoptopic effect of TNF by the various tyrphostins was slightly different.
TABLE 8 Prevention of TNF-α-induced apoptosis of mouse fibroblastic cells (A-9) by tyrphostins Apoptosis (%) TNF-α (0.2 ng/ml) Tyrphostins* − + None (vehicle) 9.3 28.7 AG1714 4.5 9.9 AG1801 6.6 10.2 AG126 8.3 19.4 AG1802 7.6 17.2 - B. As seen in Table 9, cell cycle analysis of the above cell cultures showed that treatment of the cells with TNF-α induced a G1 arrest. There was a direct correlation between the tyrphostins' reduction of the apoptotic effect caused by TNF and their ability to prevent G1 arrest in the cell cultures.
TABLE 9 Prevention by AG1714 of TNF-α-induced Go/G1 arrest and apoptosis in mouse fibroblastic cells (A-9) Cell cycle G1 S G2 + M Apoptosis % % Control 60.8 36.2 3.0 9.3 TNF-α (0.2 ng/ml) 85.8 7.6 6.6 28.7 AG1714 (30 μM) 58.1 38.1 3.8 4.5 TNF-α + AG1714 64.5 31.2 4.3 9.9 - The effect of tyrphostins on TNF-induced cytotoxicity was determined in vitro using A-9 cells as described in Example 39 above. In addition, the effect of tyrphostin on TNF mediated cytotoxicity in vivo was determined in mice injected with LPS (which induces TNF toxicity in vivo).E.coli LPS the concentration of 1.3 mg/mouse was injected i.p. to CD1 mice. While control mice were injected in addition with the vehicle only, the remaining mice were injected with the various tyrphostins (20 mg/kg) i.p. two hours prior to LPS injection. As seen in Table 10A, in agreement with the results shown in Example 39 above, addition of tyrphostins to the cells incubated with TNF significantly reduces the cytotoxic effect of TNF. As seen in Table 10B, most of the tyrphostins showed a significant protective effect against the LPS-induced toxicity in vivo which correlated with their activity in vitro.
TABLE 10 Effect of tyrphostins on TNF - induced cytotoxicity (in vitro) and LPS - induced lethal toxicity (in vivo) A in vitro, (live cells, % of control) TNF AG (20 μM) None 0.05 ng/ml 0.2 ng/ml 1.0 ng/ ml Control 100 41 19 6 AG1714 119 102 90 62 AG1719 102 83 58 41 AG26 107 86 64 31 AG126 107 75 49 33 AG1641 102 70 41 21 AG1720 104 53 26 11 B in vivo alive/total % alive mice 4/10 40 5/5 100 4/5 80 4/5 80 4/5 80 3/5 60 2/5 40 - IL-1 is one of the main mediators of septic shock in vivo. In order to determine the inhibitive activity of AG1714 on production of IL-1 from cells incubated with LPS, human peripheral blood monocytes (PBM) at a concentration of 2×106 cells/ml were divided into the following groups:
- i. Cells grown in growth medium alone;
- ii. Cells grown in growth medium to which AG1714 was added (20 μM);
- iii. Cells grown in growth medium to which LPS was added (10 mg/ml); and
- iv. Cells grown in growth medium with the addition of LPS (10 mg/ml) and AG1714 (20 μM). The cells were incubated for 24 hours and the amount of IL-1β was determined using the Genzyme ELISA kit.
- As seen in Table 11, which shows two experiments carried out as described above, addition of AG1714 to cells incubated with LPS significantly reduced the amount of IL-1β produced by the cells.
TABLE 11 Inhibition by AG1714 of LPS-induced IL-1β production in human peripheral mononuclear cells IL-1β pg/ml AG1714 (20 μM) Exp. 1 − + None 2522 1174 LPS (10 μg/ml) 10187 1230 Exp. 2 − − None 583 648 LPS (10 μg/ml) 9309 970 - The above results indicate that tyrphostins may be useful in reducing, the non desired IL-1 mediated effect involved in septic shock.
- The results of the above three examples indicate that tyrphostins may be useful in reducing or preventing the development of septic shock during an inflammatory response. The tyrphostins may also be useful as anti-inflammatory agents and in counteracting pathogenic effects mediated by various cytokines (c.g. TNF and IL-1) which occur for example in autoimmunity.
Claims (27)
1. Pharmaceutical compositions for countering damage to cells or tissue comprising an effective amount of a compound of the general formula
wherein:
Ar is a group of the formulae
n is 0 or, when Ar has the formula (i) above, then n may also be 1,
R is CN, —C(S)NH2, —C(O)NHR3 or, when R1 is 4-NO2 and R2 is H or 3-OH, then R may also be a group of the formula
where R3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
R1 and R2 are each independently H, OH, NO2 or, when R is CN, also CH3, F, or CF3, provided that both R1 and R2 arc not simultaneously H, together with a pharmaceutically acceptable carrier.
3. Pharmaceutical compositions according to claim 1 or 2, for countering damage caused by a cytotoxic drug.
4. Pharmaceutical compositions according, to claim 3 for countering damage caused by an anti-neoplastic drug.
5. Pharmaceutical compositions according to claim 3 or 4 comprising, an effective amount of a compounds of formula I in claim 1 , in combination with a cytotoxic drug.
6. Pharmaceutical compositions according to any one of claims 3-5, wherein the drug is selected from the group consisting of cisplatin, doxorubicin, cyclophosphamide, mitomycin-C and 5-fluorouracil.
7. A pharmaceutical composition according to any one of claims 1-6, for countering, myelotoxicity and lymphotoxicity.
8. Pharmaceutical compositions according to any of the preceding claims in a form suitable for intravenous administration.
9. Pharmaceutical compositions according to any of the preceding claims in a form suitable for oral administration.
10. Pharmaceutical compositions according to claim 1 or 2, for use in ex vivo preservation of cells, tissue or organ.
11. Pharmaceutical compositions according to claim 1 or 2, for countering damage caused by an immune mediated or inflammatory response.
12. A pharmaceutical composition according to any one of claims 1-10, for countering undesired apoptosis.
13. A method of treatment of an individual for countering damage to cells, tissue or organ, said method comprising administering to the individual an effective amount of a compound of the general formula
wherein:
Ar is a group of the formulae
n is 0 or, when Ar has the formula (i) above, then n may also be 1,
R is CN, —C(S)NH2, —C(O)NHR3 or, when R1 is 4-NO2 and R2 is H or 3-OH, then R may also be a group of the formula
where R3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
R1 and R2 arc each independently H, OH, NO2 or, when R is CN, also CH3, F, or CF3, provided that both R1 and R2 are not simultaneously H, together with a pharmaceutically acceptable carrier.
15. A method according to claim 13 or 14, wherein the harmful agent is a cytotoxic drug.
16. A method according to claim 15 , wherein the anti-cytotoxic drug is an anti-neoplastic drug.
17. A method according to claim 16 , wherein the cytotoxic drug is selected from the group consisting of cisplatin, doxorubicin, cyclophosphamide, mitomycin-C and 5-fluorouracil.
18. A method according to any one of claims 13-17, for countering myelotoxicity and lymphotoxicity.
19. A method according to claim 12 , for counting undesired harmful effects of irradiation treatment.
20. A method according to any one of claims 13 to 19 , wherein the compound of formula I is administered in combination with the cytotoxic drug or irradiation treatment.
21. A method according to any one of claims 1 to 20 , wherein the compound of formula I is administered prior to the administration of the cytotoxic drug or the irradiation treatment.
22. A method according to any one of claims 13 to 21 , wherein the compound of formula I is administered intravenously.
23. A method according to any one of claims 13 to 21 , wherein the compounds of formula I is administered orally.
24. A method according to claim 13 or 14, for countering damage caused by an immune mediated or inflammatory response.
25. A method for ex vivo preservation of organ, tissue or cells comprising contacting the organ, tissue or cells en vivo with a compound of the general formula
wherein:
Ar is a group of the formulae
n is 0 or, when Ar has the formula (i) above, then n may also be 1,
R is CN, —C(S)NH2, —C(O)NHR3 or, when R1 is 4-NO2 and R2 is H or 3-OH, then R may also be a group of the formula
where R3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl;
R1 and R2 are each independently H, OH, NO2 or, when R is CN, also CH3, F, or CF3, provided that both R1 and R2 are not simultaneously H, together with a pharmaceutically acceptable carrier.
26. Compound of the general formula
wherein
Ar is a group of the formula
n is 0, or, when Ar has the formula (i) above, then n may also be 1,
R is —CN, —C(S)NH2, —C(O)NHR3 or, where R1 is 4-NO2 and R2 is H, then R may also be a group of the formulae
R1 and R2 are each independently H, OH, NO2 or, when R is CN, also CH3, F or CF3; and
R3 is H, phenyl, phenyl(lower alkyl) or pyridylmethyl; with the provisos that:
a) when R is CN and n is 0, then
(aa) if one of R1 and R2 is H or OH, then the other cannot represent NO2;
(ab) if one of R1 and R2 is H or F, then the other cannot represent H or F; and
b) when R1 is 4-NO2, R2 is H and n is 0, then R cannot represent —C(O)NH2 or —C(S)NH2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/141,086 US20030013748A1 (en) | 1996-08-14 | 2002-05-09 | Pharmaceutical compositions comprising tyrphostins |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL119069 | 1996-08-14 | ||
IL11906996A IL119069A0 (en) | 1996-08-14 | 1996-08-14 | Pharmaceutical composition comprising tyrphostins |
US09/242,342 US6426366B1 (en) | 1996-08-14 | 1997-08-14 | Pharmaceutical compositions comprising tyrphostins |
US10/141,086 US20030013748A1 (en) | 1996-08-14 | 2002-05-09 | Pharmaceutical compositions comprising tyrphostins |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/242,342 Continuation US6426366B1 (en) | 1996-08-14 | 1997-08-14 | Pharmaceutical compositions comprising tyrphostins |
PCT/IL1997/000276 Continuation WO1998006391A1 (en) | 1996-08-14 | 1997-08-14 | Pharmaceutical compositions comprising tyrphostins |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030013748A1 true US20030013748A1 (en) | 2003-01-16 |
Family
ID=11069189
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/242,342 Expired - Fee Related US6426366B1 (en) | 1996-08-14 | 1997-08-14 | Pharmaceutical compositions comprising tyrphostins |
US10/141,086 Abandoned US20030013748A1 (en) | 1996-08-14 | 2002-05-09 | Pharmaceutical compositions comprising tyrphostins |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/242,342 Expired - Fee Related US6426366B1 (en) | 1996-08-14 | 1997-08-14 | Pharmaceutical compositions comprising tyrphostins |
Country Status (11)
Country | Link |
---|---|
US (2) | US6426366B1 (en) |
EP (1) | EP0923371B1 (en) |
JP (1) | JP2001504085A (en) |
CN (1) | CN1232392A (en) |
AT (1) | ATE266398T1 (en) |
AU (1) | AU728672B2 (en) |
BR (1) | BR9711160A (en) |
CA (1) | CA2263325A1 (en) |
DE (1) | DE69729104D1 (en) |
IL (1) | IL119069A0 (en) |
WO (1) | WO1998006391A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050277680A1 (en) * | 2003-12-11 | 2005-12-15 | Board Of Regents, The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US20070232668A1 (en) * | 2006-03-31 | 2007-10-04 | The Board Of Regents Of The University Of Texas System | Orally Bioavailable Caffeic Acid Related Anticancer Drugs |
US20100292229A1 (en) * | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
US8637675B2 (en) | 2008-07-08 | 2014-01-28 | Board Of Regents, The University Of Texas System | Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS) |
WO2019094689A1 (en) | 2017-11-10 | 2019-05-16 | Board Of Regents, The University Of Texas System | Caffeic acid derivatives for treating hyperproliferative diseases |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1146869A2 (en) * | 1999-01-27 | 2001-10-24 | University Of South Florida | Inhibition of stat3 signal transduction for human cancer therapy |
AU780844B2 (en) * | 1999-10-12 | 2005-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
US20040052762A1 (en) * | 2001-09-10 | 2004-03-18 | Hua Yu | Stat3 agonists and antagonists and therapeutic uses thereof |
IL159270A0 (en) * | 2001-06-14 | 2004-06-01 | Yissum Res Dev Co | Non-myeloablative tolerogenic treatment with tyrphostins |
US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
US7638122B2 (en) * | 2003-03-07 | 2009-12-29 | University Of South Florida | Stat3 antagonists and their use as vaccines against cancer |
ES2368741T3 (en) * | 2004-02-25 | 2011-11-21 | Dana-Farber Cancer Institute, Inc. | INHIBITORS OF THE RECEPTOR 1 OF THE INSULIN TYPE GROWTH FACTOR TO INHIBIT THE GROWTH OF TUMOR CELLS. |
EP2282739A2 (en) * | 2008-05-05 | 2011-02-16 | Schering Corporation | Sequential administration of chemotherapeutic agents for treatment of cancer |
WO2011080261A1 (en) | 2009-12-28 | 2011-07-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for improved cardiomyogenic differentiation of pluripotent cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3726662A (en) * | 1970-01-14 | 1973-04-10 | Monsanto Co | Herbicidal anilinomethylene-malononitriles |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH484603A (en) | 1966-03-21 | 1970-01-31 | Ciba Geigy | Pesticides containing certain malodinitriles |
US3551573A (en) | 1967-11-08 | 1970-12-29 | Monsanto Co | Insecticidal composition and method containing anilinomethylene malonitriles |
NL7800191A (en) * | 1977-01-10 | 1978-07-12 | Ciba Geigy | ANTHELMINTIC PREPARATION. |
AU632992B2 (en) * | 1987-12-24 | 1993-01-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation |
RU2024514C1 (en) | 1991-10-01 | 1994-12-15 | Иркутский институт органической химии СО РАН | Complex of 1-ethylimidazole with zinc ascorbate increasing organism resistance to nitrogen dioxide action and showing cytoprotective and antihypoxic effect |
US5284868A (en) | 1991-10-09 | 1994-02-08 | Eli Lilly And Company | Pharmaceutical compounds |
US5972598A (en) | 1992-09-17 | 1999-10-26 | Board Of Trustess Of The University Of Illinois | Methods for preventing multidrug resistance in cancer cells |
WO1995002420A2 (en) * | 1993-07-15 | 1995-01-26 | Cancer Research Campaign Technology Ltd. | Prodrugs of protein tyrosine kinase inhibitors |
IL107736A (en) * | 1993-11-24 | 2001-01-11 | Yissum Res Dev Co | Pharmaceutical composition for the prevention of septic shock and for the treatment of chronic inflammatory diseases |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
WO1995024190A2 (en) * | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
EP0850055B1 (en) * | 1995-09-11 | 2005-06-29 | Osteoarthritis Sciences, Inc. | Protein tyrosine kinase inhibitors for treating osteoarthritis |
-
1996
- 1996-08-14 IL IL11906996A patent/IL119069A0/en unknown
-
1997
- 1997-08-14 DE DE69729104T patent/DE69729104D1/en not_active Expired - Lifetime
- 1997-08-14 BR BR9711160-0A patent/BR9711160A/en unknown
- 1997-08-14 AT AT97934696T patent/ATE266398T1/en not_active IP Right Cessation
- 1997-08-14 JP JP50955898A patent/JP2001504085A/en active Pending
- 1997-08-14 EP EP97934696A patent/EP0923371B1/en not_active Expired - Lifetime
- 1997-08-14 AU AU37822/97A patent/AU728672B2/en not_active Ceased
- 1997-08-14 WO PCT/IL1997/000276 patent/WO1998006391A1/en active IP Right Grant
- 1997-08-14 CA CA002263325A patent/CA2263325A1/en not_active Abandoned
- 1997-08-14 US US09/242,342 patent/US6426366B1/en not_active Expired - Fee Related
- 1997-08-14 CN CN97198596A patent/CN1232392A/en active Pending
-
2002
- 2002-05-09 US US10/141,086 patent/US20030013748A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3726662A (en) * | 1970-01-14 | 1973-04-10 | Monsanto Co | Herbicidal anilinomethylene-malononitriles |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2487156A1 (en) | 2003-12-11 | 2012-08-15 | Board Of Regents The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US9096499B2 (en) * | 2003-12-11 | 2015-08-04 | Board Of Regents, The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US20050277680A1 (en) * | 2003-12-11 | 2005-12-15 | Board Of Regents, The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US7745468B2 (en) | 2003-12-11 | 2010-06-29 | Board of Regents, University of Texas Systems The | Compounds for treatment of cell proliferative diseases |
US8648102B2 (en) | 2003-12-11 | 2014-02-11 | Board Of Regents, The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US20110021805A1 (en) * | 2003-12-11 | 2011-01-27 | The Board Of Regents Of The University Of Texas System | Compounds for treatment of cell proliferative diseases |
US8119827B2 (en) | 2003-12-11 | 2012-02-21 | Board Of Regents, The University Of Texas System | Compounds for treatment of cell proliferative diseases |
JP2015007070A (en) * | 2006-03-31 | 2015-01-15 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | Orally bioavailable caffeic acid related anticancer drugs |
EP2514742A2 (en) | 2006-03-31 | 2012-10-24 | The Board of Regents of The University of Texas System | Orally bioavailable cafeic acid related anticancer drugs |
US8779151B2 (en) | 2006-03-31 | 2014-07-15 | The Board Of Regents Of The University Of Texas System | Orally bioavailable caffeic acid related anticancer drugs |
WO2007115269A3 (en) * | 2006-03-31 | 2007-12-21 | Univ Texas | Orally bioavailable caffeic acid related anticancer drugs |
US20070232668A1 (en) * | 2006-03-31 | 2007-10-04 | The Board Of Regents Of The University Of Texas System | Orally Bioavailable Caffeic Acid Related Anticancer Drugs |
US20100292229A1 (en) * | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
US8637675B2 (en) | 2008-07-08 | 2014-01-28 | Board Of Regents, The University Of Texas System | Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS) |
US9000179B2 (en) | 2008-07-08 | 2015-04-07 | Board Of Regents, The University Of Texas System | Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs) |
WO2019094689A1 (en) | 2017-11-10 | 2019-05-16 | Board Of Regents, The University Of Texas System | Caffeic acid derivatives for treating hyperproliferative diseases |
US10703721B2 (en) | 2017-11-10 | 2020-07-07 | Board Of Regents, The University Of Texas System | Caffeic acid derivatives and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
DE69729104D1 (en) | 2004-06-17 |
JP2001504085A (en) | 2001-03-27 |
IL119069A0 (en) | 1996-11-14 |
EP0923371B1 (en) | 2004-05-12 |
AU728672B2 (en) | 2001-01-18 |
US6426366B1 (en) | 2002-07-30 |
CA2263325A1 (en) | 1998-02-19 |
BR9711160A (en) | 2000-01-11 |
AU3782297A (en) | 1998-03-06 |
EP0923371A1 (en) | 1999-06-23 |
CN1232392A (en) | 1999-10-20 |
ATE266398T1 (en) | 2004-05-15 |
WO1998006391A1 (en) | 1998-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6426366B1 (en) | Pharmaceutical compositions comprising tyrphostins | |
US5676978A (en) | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent | |
US6482802B1 (en) | Use of neomycin for treating angiogenesis-related diseases | |
AU2927999A (en) | Use of epothilones for the treatment of cancer | |
SK282228B6 (en) | A pharmaceutical composition and its use | |
WO1999034796A1 (en) | Synergistic antitumor composition containing a naphthalensulphonic acid derivative | |
US7851443B2 (en) | Combination comprising combretastatin and anticancer agents | |
US20210069192A1 (en) | Use of neutrophil elastase inhibitors in liver disease | |
Taylor et al. | Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer | |
US4963559A (en) | Method of treating cancer and cancer metastasis | |
US7759313B2 (en) | Induction method for cell differentiation | |
JP6370801B2 (en) | Uses and methods for the treatment of liver disease or disorder | |
CN110613713B (en) | 3-hydroxyaminobenzoic acid and sorafenib combined medicine for treating tumor | |
KR100459484B1 (en) | Radiosensitizer composition containing N-acetylphytosphingosine and dimethylphytosphingosine as the active ingredients | |
JP2003511396A (en) | How to enhance chemotherapy | |
US8642580B2 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and platinum derivatives | |
US6355639B1 (en) | Reverse prenyl compounds as immunosuppressants | |
MXPA99001505A (en) | Pharmaceutical compositions comprising tyrphostins | |
KR100861668B1 (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites | |
KR100457113B1 (en) | Radiosensitizer containing ceramides or derivatives thereof and dimethylsphingosine as the active ingredient | |
KR100421261B1 (en) | Radiosensitizer containing phytosphingosine derivatives as the active ingredient | |
Sanchez et al. | Use of desferoxamine and S-adenosylmethionine to treat hemochromatosis in a red ruffed lemur (Varecia variegata ruber) | |
BG100385A (en) | The use of benzidamine for the treatment of pathological conditions caused by tumournecrotic factor | |
US20060009475A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
Steinfeld et al. | Negative effects of some metabolite analogs in human neoplasms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |